Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,18420784,T(max),"After a 100-mg single p.o. dose of [(14)C]dasatinib to healthy volunteers, the radioactivity was rapidly absorbed (T(max) approximately 0.5 h).",Metabolism and disposition of dasatinib after oral administration to humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18420784/),h,0.5,567,DB00619,Imatinib
<,18420784,elimination half-life,Both dasatinib and total radioactivity (TRA) plasma concentrations decreased rapidly with elimination half-life values of <4 h.,Metabolism and disposition of dasatinib after oral administration to humans. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18420784/),h,4,568,DB00619,Imatinib
,19293394,PFS,"Overall median PFS was 2 months (range, 0.7-34 months); 6M-PFS was 29.4%.",Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293394/),month,2,1697,DB00619,Imatinib
,19293394,PFS,"For benign meningiomas, median PFS was 3 months (range, 1.1-34 months); 6M-PFS was 45%.",Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293394/),month,3,1698,DB00619,Imatinib
,19293394,PFS,"For atypical and malignant meningiomas, median PFS was 2 months (range, 0.7-3.7 months); 6M-PFS was 0%.",Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293394/),month,2,1699,DB00619,Imatinib
,19293394,trough concentrations,"Cycle 1 trough concentrations of imatinib and CGP74588 were 2,129 +/- 1,600 ng/ml and 517 +/- 326 ng/ml, respectively.",Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293394/),[ng] / [ml],"2,129",1700,DB00619,Imatinib
,19293394,trough concentrations,"Cycle 1 trough concentrations of imatinib and CGP74588 were 2,129 +/- 1,600 ng/ml and 517 +/- 326 ng/ml, respectively.",Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293394/),[ng] / [ml],517,1701,DB00619,Imatinib
,17062683,area under the curve (AUC) ratio,"A significant time-dependent decrease in CLM/fm was evidenced with a mean (+SD) CGP 74588/imatinib area under the curve (AUC) ratio of 0.25 (+/-0.07) at steady state, compared with 0.14 (+/-0.03) on day 1.",Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17062683/),,0.25,6677,DB00619,Imatinib
,17062683,area under the curve (AUC) ratio,"A significant time-dependent decrease in CLM/fm was evidenced with a mean (+SD) CGP 74588/imatinib area under the curve (AUC) ratio of 0.25 (+/-0.07) at steady state, compared with 0.14 (+/-0.03) on day 1.",Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17062683/),,0.14,6678,DB00619,Imatinib
,15537555,Protein binding,"Protein binding ranged from 97.7-90.3% (mean 94.9%), was concentration independent, and was not altered by St. John's wort.",The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537555/),%,97.7-90.3,7713,DB00619,Imatinib
,15537555,Protein binding,"Protein binding ranged from 97.7-90.3% (mean 94.9%), was concentration independent, and was not altered by St. John's wort.",The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537555/),%,94.9,7714,DB00619,Imatinib
,22000961,detection limits,"The detection limits were 20 ng/mL and 10 ng/mL for M1 and IM, respectively.",Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22000961/),[ng] / [ml],20,7914,DB00619,Imatinib
,22000961,detection limits,"The detection limits were 20 ng/mL and 10 ng/mL for M1 and IM, respectively.",Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22000961/),[ng] / [ml],10,7915,DB00619,Imatinib
more,22000961,percent recoveries,The intra- and inter-day precisions were less than 1% with percent recoveries of more than 90%.,Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22000961/),%,90,7916,DB00619,Imatinib
,26799978,flow rate,"The analyte and IS were separated on a C18 reverse phase analytical column with 4.5 min of analytical run, at flow rate of 0.3 mL/min.",Preclinical pharmacokinetics and tissue distribution of a novel multikinase inhibitor BZG by validated UPLC-MS/MS assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26799978/),[ml] / [min],0.3,8520,DB00619,Imatinib
,20520639,times,"Median times from diagnosis of CP or AP to nilotinib therapy were 89 and 83 months, respectively.",Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20520639/),month,89,12771,DB00619,Imatinib
,20520639,times,"Median times from diagnosis of CP or AP to nilotinib therapy were 89 and 83 months, respectively.",Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20520639/),month,83,12772,DB00619,Imatinib
,21827214,Absolute bioavailability,Absolute bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).,"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,100,12901,DB00619,Imatinib
,21827214,Absolute bioavailability,Absolute bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).,"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,14-39,12902,DB00619,Imatinib
,21827214,absolute bioavailability,"Quite low absolute bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,31,12903,DB00619,Imatinib
,21827214,absolute bioavailability,"Quite low absolute bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,50,12904,DB00619,Imatinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,1.5-2.5,12905,DB00619,Imatinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,2.0,12906,DB00619,Imatinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,3,12907,DB00619,Imatinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,1.2-4.5,12908,DB00619,Imatinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,5.7-6.4,12909,DB00619,Imatinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,3.0-4.5,12910,DB00619,Imatinib
,21419933,elimination half-life,"These studies show that the maximum plasma concentration of nilotinib is reached 3 to 4 hours after oral administration, with an elimination half-life of 17 hours through metabolism via oxidation and hydroxylation.",Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21419933/),h,17,13128,DB00619,Imatinib
,16842382,oral clearance,"A one-compartment model with first-order absorption appropriately described the data, giving a mean (+/-SEM) oral clearance of 14.3 l h-1 (+/-1.0) and a volume of distribution of 347 l (+/-62).",Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842382/),[l] / [h],14.3,14072,DB00619,Imatinib
,16842382,volume of distribution,"A one-compartment model with first-order absorption appropriately described the data, giving a mean (+/-SEM) oral clearance of 14.3 l h-1 (+/-1.0) and a volume of distribution of 347 l (+/-62).",Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842382/),l,347,14073,DB00619,Imatinib
,16842382,intra/extracellular ratio,"Moreover, we observed an intra/extracellular ratio of 8, suggesting substantial uptake of the drug into the target cells.",Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842382/),,8,14074,DB00619,Imatinib
,24814993,m/,The ion transitions used to monitor analytes were m/z 490.2âm/z 255.2 and m/z 383.3 for vemurafenib and m/z 496.2âm/z 261.2 and m/z 389.3 for vemurafenib-(13)C6.,A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24814993/),,490.2,14365,DB00619,Imatinib
,24814993,m/,The ion transitions used to monitor analytes were m/z 490.2âm/z 255.2 and m/z 383.3 for vemurafenib and m/z 496.2âm/z 261.2 and m/z 389.3 for vemurafenib-(13)C6.,A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24814993/),,255.2,14366,DB00619,Imatinib
,24814993,m/z,The ion transitions used to monitor analytes were m/z 490.2âm/z 255.2 and m/z 383.3 for vemurafenib and m/z 496.2âm/z 261.2 and m/z 389.3 for vemurafenib-(13)C6.,A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24814993/),,496.2,14367,DB00619,Imatinib
,24814993,m/z,The ion transitions used to monitor analytes were m/z 490.2âm/z 255.2 and m/z 383.3 for vemurafenib and m/z 496.2âm/z 261.2 and m/z 389.3 for vemurafenib-(13)C6.,A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24814993/),,261.2,14368,DB00619,Imatinib
,24814993,m/z,The ion transitions used to monitor analytes were m/z 490.2âm/z 255.2 and m/z 383.3 for vemurafenib and m/z 496.2âm/z 261.2 and m/z 389.3 for vemurafenib-(13)C6.,A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24814993/),,389.3,14369,DB00619,Imatinib
,24814993,m/,The ion transitions used to monitor analytes were m/z 490.2âm/z 255.2 and m/z 383.3 for vemurafenib and m/z 496.2âm/z 261.2 and m/z 389.3 for vemurafenib-(13)C6.,A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24814993/),,389.3,14370,DB00619,Imatinib
,31536852,PFS,"At the cut-off date, the median PFS was 4.4 months (95% confidence interval [CI], 2.8-6.0) and 12-week progression-free rate was 73.4% (95% CI, 58.1-88.7).","Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31536852/),month,4,16206,DB00619,Imatinib
,31536852,OS,"The median OS was 11.5 months (95% CI, 7.0-not reached).","Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31536852/),month,11.5,16207,DB00619,Imatinib
,29880085,bioavailability,"The total clearance (CL/F) of oral and intravenous given IMA was increased by 1.41 and 1.32-fold, and the bioavailability was greatly decreased about 30.43% and 24.40% respectively.",Effects of aprepitant on the pharmacokinetics of imatinib and its main metabolite in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29880085/),%,30.43,17060,DB00619,Imatinib
,29880085,bioavailability,"The total clearance (CL/F) of oral and intravenous given IMA was increased by 1.41 and 1.32-fold, and the bioavailability was greatly decreased about 30.43% and 24.40% respectively.",Effects of aprepitant on the pharmacokinetics of imatinib and its main metabolite in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29880085/),%,24.40,17061,DB00619,Imatinib
,23715577,time to reach maximum concentration,"Dasatinib pediatric pharmacokinetic parameters were comparable with those in adult studies, showing rapid absorption (time to reach maximum concentration, 0.5 to 6.0 hours) and elimination (mean half-life, 3.0 to 4.4 hours).",Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715577/),h,0.5 to 6.0,17096,DB00619,Imatinib
,23715577,half-life,"Dasatinib pediatric pharmacokinetic parameters were comparable with those in adult studies, showing rapid absorption (time to reach maximum concentration, 0.5 to 6.0 hours) and elimination (mean half-life, 3.0 to 4.4 hours).",Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715577/),h,3.0 to 4.4,17097,DB00619,Imatinib
,32430518,absolute bioavailability,The median absolute bioavailability of oral imatinib at steady state was 76% (range 44-106%).,Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32430518/),%,76,18362,DB00619,Imatinib
,32293723,Cmin,"The imatinib Cmin was 1315 Â± 716 ng/mL, 2117 Â± 597 ng/mL, and 3844 Â± 987 ng/mL in patients who were receiving imatinib 400 mg, 600 mg, and 800 mg daily, respectively.",Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32293723/),[ng] / [ml],1315,18580,DB00619,Imatinib
,32293723,Cmin,"The imatinib Cmin was 1315 Â± 716 ng/mL, 2117 Â± 597 ng/mL, and 3844 Â± 987 ng/mL in patients who were receiving imatinib 400 mg, 600 mg, and 800 mg daily, respectively.",Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32293723/),[ng] / [ml],2117,18581,DB00619,Imatinib
,32293723,Cmin,"The imatinib Cmin was 1315 Â± 716 ng/mL, 2117 Â± 597 ng/mL, and 3844 Â± 987 ng/mL in patients who were receiving imatinib 400 mg, 600 mg, and 800 mg daily, respectively.",Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32293723/),[ng] / [ml],3844,18582,DB00619,Imatinib
,23272163,CL,"Haplotype-specific GLM estimated that the haplotypes AGT and CGC were both associated with 22% decrease in clearance compared to CAC [CL (10(-2) L/hr/mg): CAC vs AGT: 4.03 vs 3.16, p = 0.017; CAC vs CGC: 4.03 vs 3.15, p = 0.017].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),,10(,21909,DB00619,Imatinib
,23272163,CL,"Haplotype-specific GLM estimated that the haplotypes AGT and CGC were both associated with 22% decrease in clearance compared to CAC [CL (10(-2) L/hr/mg): CAC vs AGT: 4.03 vs 3.16, p = 0.017; CAC vs CGC: 4.03 vs 3.15, p = 0.017].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),,4.03,21910,DB00619,Imatinib
,23272163,CL,"Haplotype-specific GLM estimated that the haplotypes AGT and CGC were both associated with 22% decrease in clearance compared to CAC [CL (10(-2) L/hr/mg): CAC vs AGT: 4.03 vs 3.16, p = 0.017; CAC vs CGC: 4.03 vs 3.15, p = 0.017].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),,3,21911,DB00619,Imatinib
,23272163,CL,"Haplotype-specific GLM estimated that the haplotypes AGT and CGC were both associated with 22% decrease in clearance compared to CAC [CL (10(-2) L/hr/mg): CAC vs AGT: 4.03 vs 3.16, p = 0.017; CAC vs CGC: 4.03 vs 3.15, p = 0.017].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),,4,21912,DB00619,Imatinib
,23272163,CL,"Patients harboring 2 copies of AGT or CGC haplotypes had 33.4% lower clearance and 50% higher C(0h) than patients carrying 0 or 1 copy [CL (10(-2) L/hr/mg): 2.19 vs 3.29, p = 0.026; C(0h) (10(-6) 1/ml): 4.76 vs 3.17, p = 0.013, respectively].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),[l] / [hÂ·mg],2.19,21913,DB00619,Imatinib
,23272163,CL,"Patients harboring 2 copies of AGT or CGC haplotypes had 33.4% lower clearance and 50% higher C(0h) than patients carrying 0 or 1 copy [CL (10(-2) L/hr/mg): 2.19 vs 3.29, p = 0.026; C(0h) (10(-6) 1/ml): 4.76 vs 3.17, p = 0.013, respectively].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),[l] / [hÂ·mg],3.29,21914,DB00619,Imatinib
,23272163,C(0h),"Patients harboring 2 copies of AGT or CGC haplotypes had 33.4% lower clearance and 50% higher C(0h) than patients carrying 0 or 1 copy [CL (10(-2) L/hr/mg): 2.19 vs 3.29, p = 0.026; C(0h) (10(-6) 1/ml): 4.76 vs 3.17, p = 0.013, respectively].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),[1] / [(10)^6Â·ml],4.76,21915,DB00619,Imatinib
,23272163,C(0h),"Patients harboring 2 copies of AGT or CGC haplotypes had 33.4% lower clearance and 50% higher C(0h) than patients carrying 0 or 1 copy [CL (10(-2) L/hr/mg): 2.19 vs 3.29, p = 0.026; C(0h) (10(-6) 1/ml): 4.76 vs 3.17, p = 0.013, respectively].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),[1] / [(10)^6Â·ml],3.17,21916,DB00619,Imatinib
,22898035,overall response rate,The best response was PR by FDG-PET for five patients (3/12 at 600 mg BIW and 2/9 at 400 TIW) for an overall response rate of 22%.,Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22898035/),%,22,22333,DB00619,Imatinib
,22898035,response duration,The response duration was 25-138 days.,Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22898035/),d,25-138,22334,DB00619,Imatinib
,22898035,Cmax,The mean Cmax was 1.5 Âµmol and the mean AUC was 2.9 Âµmol h.,Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22898035/),Î¼M,1.5,22335,DB00619,Imatinib
,22898035,AUC,The mean Cmax was 1.5 Âµmol and the mean AUC was 2.9 Âµmol h.,Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22898035/),hÂ·Î¼M,2.9,22336,DB00619,Imatinib
>,22898035,Cmax,Cmax>1.5 Âµmol was associated with a decrease in standardized uptake value (SUVmax).,Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22898035/),Î¼M,1.5,22337,DB00619,Imatinib
,18500518,area under the plasma imatinib concentration versus time curve (AUC),"Antacid administration did not significantly affect the area under the plasma imatinib concentration versus time curve (AUC) [31.7 microg/(mL h) alone versus 32.6 microg/(mL h) with antacid, P = 0.37; 80% power].",Effect of antacid on imatinib absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18500518/),[Î¼g] / [hÂ·ml],31.7,27694,DB00619,Imatinib
,18500518,area under the plasma imatinib concentration versus time curve (AUC),"Antacid administration did not significantly affect the area under the plasma imatinib concentration versus time curve (AUC) [31.7 microg/(mL h) alone versus 32.6 microg/(mL h) with antacid, P = 0.37; 80% power].",Effect of antacid on imatinib absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18500518/),[Î¼g] / [hÂ·ml],32.6,27695,DB00619,Imatinib
,15081939,flow rate,"Assay was conducted using a C8 column (250 mm x 4.6 mm, 5 microm particle size) under isocratic elution with 0.02 M potassium dihydrogen phosphate-acetonitrile (7:3, v/v) at a flow rate of 1 ml/min and detected using photodiode array at 265 nm.",Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081939/),[ml] / [min],1,29709,DB00619,Imatinib
â¥,31886022,recovery rate,Mean recovery rate of anlotinib in plasma was â¥99.32% and reproducible.,"Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31886022/),%,99.32,31002,DB00619,Imatinib
,22891806,dissociation constant Kd,"Imatinib free concentrations were best predicted using a non-linear binding model to AGP, with a dissociation constant Kd of 319 ng ml(-1) , assuming a 1:1 molar binding ratio.",Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22891806/),[ng] / [ml],319,32407,DB00619,Imatinib
,29138287,"CLint,u","UGT2B7 and UGT2B17 exhibited the greatest level of clopidogrel carboxylic acid glucuronidation activities, with a CLint,u of 2.42 and 2.82 Âµlâmin-1âmg-1, respectively.","Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138287/),[Î¼l] / [mgÂ·min],2.42,34460,DB00619,Imatinib
,29138287,"CLint,u","UGT2B7 and UGT2B17 exhibited the greatest level of clopidogrel carboxylic acid glucuronidation activities, with a CLint,u of 2.42 and 2.82 Âµlâmin-1âmg-1, respectively.","Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138287/),[Î¼l] / [mgÂ·min],2.82,34461,DB00619,Imatinib
,29138287,CLint,"Of other enzymes displaying activity (UGT1A3, UGT1A9, UGT1A10-H, and UGT2B4), UGT2B4 (CLint,u 0.51 Âµlâmin-1âmg-1) was estimated to contribute significantly to the hepatic clearance.","Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138287/),[Î¼l] / [mgÂ·min],0.51,34462,DB00619,Imatinib
â¥,32688207,Cmin,The aim of this study is to evaluate whether pharmacokinetically (PK)-guided dose increases are feasible in daily clinical practice and result in an improved exposure (Cminâ¥1100 ng/mL) and longer progression-free survival (PFS).,Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32688207/),[ng] / [ml],1100,34814,DB00619,Imatinib
below,32688207,Cmin,"In 126 patients (75%), Cmin was below the efficacy threshold of 1100 ng/mL.",Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32688207/),[ng] / [ml],1100,34815,DB00619,Imatinib
,28411632,limit of detection,"Under optimized conditions, this sandwich ELISA shows a linear detection range from 64 pg mL-1 to 8 ng mL-1, and a limit of detection of approximately 64 pg mL-1 for 100-Î¼L samples.",An ultra-specific and sensitive sandwich ELISA for imatinib using two anti-imatinib antibodies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28411632/),[pg] / [ml],64,34901,DB00619,Imatinib
,26865926,area under the curve (AUC (0-â)),"Mean area under the curve (AUC (0-â)) values were 27011, 25811 and 25699 ng/ml for 4Ã100 mg capsules, 4Ã100 mg tablets and 1Ã400 mg tablets, respectively.",Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865926/),[ng] / [ml],27011,35917,DB00619,Imatinib
,26865926,area under the curve (AUC (0-â)),"Mean area under the curve (AUC (0-â)) values were 27011, 25811 and 25699 ng/ml for 4Ã100 mg capsules, 4Ã100 mg tablets and 1Ã400 mg tablets, respectively.",Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865926/),[ng] / [ml],25811,35918,DB00619,Imatinib
,26865926,area under the curve (AUC (0-â)),"Mean area under the curve (AUC (0-â)) values were 27011, 25811 and 25699 ng/ml for 4Ã100 mg capsules, 4Ã100 mg tablets and 1Ã400 mg tablets, respectively.",Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865926/),[ng] / [ml],25699,35919,DB00619,Imatinib
,26865926,Cmax,"Cmax values were 1548, 1605 and 1622 ng/ml and t1/2 values were 15.7, 15.8 and 15.6 h.",Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865926/),[ng] / [ml],1548,35920,DB00619,Imatinib
,26865926,Cmax,"Cmax values were 1548, 1605 and 1622 ng/ml and t1/2 values were 15.7, 15.8 and 15.6 h.",Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865926/),[ng] / [ml],1605,35921,DB00619,Imatinib
,26865926,Cmax,"Cmax values were 1548, 1605 and 1622 ng/ml and t1/2 values were 15.7, 15.8 and 15.6 h.",Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865926/),[ng] / [ml],1622,35922,DB00619,Imatinib
,26865926,t1/2,"Cmax values were 1548, 1605 and 1622 ng/ml and t1/2 values were 15.7, 15.8 and 15.6 h.",Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865926/),h,15.7,35923,DB00619,Imatinib
,26865926,t1/2,"Cmax values were 1548, 1605 and 1622 ng/ml and t1/2 values were 15.7, 15.8 and 15.6 h.",Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865926/),h,15.8,35924,DB00619,Imatinib
,26865926,t1/2,"Cmax values were 1548, 1605 and 1622 ng/ml and t1/2 values were 15.7, 15.8 and 15.6 h.",Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865926/),h,15.6,35925,DB00619,Imatinib
,25540064,PFS,PFS and OS rates at week 96 were 21 and 43 %.,A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25540064/),%,21,36679,DB00619,Imatinib
,25540064,OS rates,PFS and OS rates at week 96 were 21 and 43 %.,A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25540064/),%,43,36680,DB00619,Imatinib
,31119479,overall PFS6,"For phase II patients, overall PFS6 was 33% and median PFS 4.0 months (95% CI 2.1, 5.7).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),%,33,37646,DB00619,Imatinib
,31119479,PFS,"For phase II patients, overall PFS6 was 33% and median PFS 4.0 months (95% CI 2.1, 5.7).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),month,4,37647,DB00619,Imatinib
,31119479,overall survival (OS),"Median overall survival (OS) was longer in imatinib-treated patients compared with controls (16.6 vs. 8.0 months; HR = 0.64, 95% CI 0.41,1.0, p = 0.049), and longer in patients with 1p/19q-codeleted tumors (19.2 vs. 6.2 months, HR = 0.43, 95% CI 0.21,0.89, p = 0.019).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),month,16.6,37648,DB00619,Imatinib
,31119479,overall survival (OS),"Median overall survival (OS) was longer in imatinib-treated patients compared with controls (16.6 vs. 8.0 months; HR = 0.64, 95% CI 0.41,1.0, p = 0.049), and longer in patients with 1p/19q-codeleted tumors (19.2 vs. 6.2 months, HR = 0.43, 95% CI 0.21,0.89, p = 0.019).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),month,8.0,37649,DB00619,Imatinib
,31119479,overall survival (OS),"Median overall survival (OS) was longer in imatinib-treated patients compared with controls (16.6 vs. 8.0 months; HR = 0.64, 95% CI 0.41,1.0, p = 0.049), and longer in patients with 1p/19q-codeleted tumors (19.2 vs. 6.2 months, HR = 0.43, 95% CI 0.21,0.89, p = 0.019).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),month,19.2,37650,DB00619,Imatinib
,31119479,overall survival (OS),"Median overall survival (OS) was longer in imatinib-treated patients compared with controls (16.6 vs. 8.0 months; HR = 0.64, 95% CI 0.41,1.0, p = 0.049), and longer in patients with 1p/19q-codeleted tumors (19.2 vs. 6.2 months, HR = 0.43, 95% CI 0.21,0.89, p = 0.019).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),month,6.2,37651,DB00619,Imatinib
,31119479,Confirmed response rate,"Confirmed response rate was 3.9% (PR = 1; REGR = 1), with stable disease observed in 52.9%.",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),%,3.9,37652,DB00619,Imatinib
,31119479,steady-state imatinib plasma concentration,"At 600 mg/D, mean steady-state imatinib plasma concentration was 2513 ng/ml (95% CI 1831,3195).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),[ng] / [ml],2513,37653,DB00619,Imatinib
above,19737946,total drug trough concentrations,"On the 50-mg dose across all schedules, 79% of PK-evaluable patients achieved total drug trough concentrations above the target concentration (50 ng/mL) within 14 days of dosing.","Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19737946/),[ng] / [ml],50,39980,DB00619,Imatinib
,30081867,MTD,The MTD of quizartinib in patients with advanced solid tumors was 90 mg/day.,"Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081867/),[mg] / [d],90,40044,DB00619,Imatinib
,28238945,brain/plasma ratio,"Following intravenous administration, the brain/plasma ratio for imatinib was calculated to be 2% and remained at this ratio for 30min.",Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28238945/),%,2,40263,DB00619,Imatinib
,28238945,brain/plasma ratio,"The brain/plasma ratio following intranasal administration, however, was found to be 5.3% and remained at this ratio for up to 90min.",Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28238945/),%,5.3,40264,DB00619,Imatinib
,14605865,excretion,All subjects demonstrated a marked induction of hepatic microsomal CYP3A analyzed by the excretion ratio of 6beta-hydroxycortisol to cortisol from a mean baseline concentration of 5.6 U to 50.5 U.,"Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14605865/),,50,40758,DB00619,Imatinib
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1404,43042,DB00619,Imatinib
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1374,43043,DB00619,Imatinib
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1400,43044,DB00619,Imatinib
,18781906,trough levels,"Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],477,43045,DB00619,Imatinib
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],240,43046,DB00619,Imatinib
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],351,43047,DB00619,Imatinib
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],356,43048,DB00619,Imatinib
,19451435,TTP,"The median TTP was 11.3 months for patients in the lowest C(min) quartile (Q1, < 1,110 ng/mL) compared with more than 30 months for Q2 to Q4 (P = .0029).",Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451435/),month,11.3,43195,DB00619,Imatinib
more,19451435,TTP,"The median TTP was 11.3 months for patients in the lowest C(min) quartile (Q1, < 1,110 ng/mL) compared with more than 30 months for Q2 to Q4 (P = .0029).",Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451435/),month,30,43196,DB00619,Imatinib
,19451435,OOBR,"In patients with GIST with KIT exon 11 mutations (n = 39), the OOBR was 67% for Q1 patients versus 100% for all others (P = .001).",Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451435/),%,67,43197,DB00619,Imatinib
,19451435,OOBR,"In patients with GIST with KIT exon 11 mutations (n = 39), the OOBR was 67% for Q1 patients versus 100% for all others (P = .001).",Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451435/),%,100,43198,DB00619,Imatinib
below,19451435,C(min),"Patients with IM C(min) below 1,100 ng/mL showed a shorter TTP and lower rate of clinical benefit (OOBR).",Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451435/),[ng] / [ml],"1,100",43199,DB00619,Imatinib
,33851349,major molecular response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,63.6,44834,DB00619,Imatinib
,33851349,major molecular response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,38.2,44835,DB00619,Imatinib
,33851349,major molecular response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,60.9,44836,DB00619,Imatinib
,33851349,major molecular response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,52.6,44837,DB00619,Imatinib
,33851349,complete cytogenetic response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,86.7,44838,DB00619,Imatinib
,33851349,complete cytogenetic response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,76.7,44839,DB00619,Imatinib
,33851349,complete cytogenetic response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,81.5,44840,DB00619,Imatinib
,33851349,complete cytogenetic response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,76.3,44841,DB00619,Imatinib
,14577318,maximum concentration,"The pharmacokinetics revealed that the maximum concentration (1.4 micrograms/ml); time to maximum concentration (5.1 h); half-life (11.0 h); trough concentration (0.4 microgram/ml); and, area under the concentration-time curve (28.1 micrograms.h/ml) were inferior to those for adult patients in the 400 mg/day group.",[Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14577318/),[Î¼g] / [ml],1.4,46080,DB00619,Imatinib
,14577318,time to maximum concentration,"The pharmacokinetics revealed that the maximum concentration (1.4 micrograms/ml); time to maximum concentration (5.1 h); half-life (11.0 h); trough concentration (0.4 microgram/ml); and, area under the concentration-time curve (28.1 micrograms.h/ml) were inferior to those for adult patients in the 400 mg/day group.",[Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14577318/),h,5.1,46081,DB00619,Imatinib
,14577318,half-life,"The pharmacokinetics revealed that the maximum concentration (1.4 micrograms/ml); time to maximum concentration (5.1 h); half-life (11.0 h); trough concentration (0.4 microgram/ml); and, area under the concentration-time curve (28.1 micrograms.h/ml) were inferior to those for adult patients in the 400 mg/day group.",[Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14577318/),h,11.0,46082,DB00619,Imatinib
,14577318,trough concentration,"The pharmacokinetics revealed that the maximum concentration (1.4 micrograms/ml); time to maximum concentration (5.1 h); half-life (11.0 h); trough concentration (0.4 microgram/ml); and, area under the concentration-time curve (28.1 micrograms.h/ml) were inferior to those for adult patients in the 400 mg/day group.",[Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14577318/),[Î¼g] / [ml],0.4,46083,DB00619,Imatinib
,14577318,area under the concentration-time curve,"The pharmacokinetics revealed that the maximum concentration (1.4 micrograms/ml); time to maximum concentration (5.1 h); half-life (11.0 h); trough concentration (0.4 microgram/ml); and, area under the concentration-time curve (28.1 micrograms.h/ml) were inferior to those for adult patients in the 400 mg/day group.",[Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14577318/),[hÂ·Î¼g] / [ml],28.1,46084,DB00619,Imatinib
,25365188,IC50,"Also, silybin showed inhibitory effect on human and rat microsomes, the IC50 of silybin were 26.42 Î¼molÂ·L(-1) and 49.12 Î¼molÂ·L(-1) in human and rat liver microsomes, respectively.",Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25365188/),[Î¼M] / [l],26.42,47008,DB00619,Imatinib
,25365188,IC50,"Also, silybin showed inhibitory effect on human and rat microsomes, the IC50 of silybin were 26.42 Î¼molÂ·L(-1) and 49.12 Î¼molÂ·L(-1) in human and rat liver microsomes, respectively.",Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25365188/),[Î¼M] / [l],49.12,47009,DB00619,Imatinib
,24817601,Oral clearance (CL/F),"Oral clearance (CL/F) and the volume of distribution (V/F) were estimated to 10.8 L/h with 30 % IIV and 265 L with 53 % IIV, respectively.",Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24817601/),[l] / [h],10.8,47106,DB00619,Imatinib
,24817601,volume of distribution (V/F),"Oral clearance (CL/F) and the volume of distribution (V/F) were estimated to 10.8 L/h with 30 % IIV and 265 L with 53 % IIV, respectively.",Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24817601/),l,265,47107,DB00619,Imatinib
<,24817601,trough plasma levels,"Imatinib trough plasma levels <1,257 ng/mL were associated with lower rates of major molecular response.",Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24817601/),[ng] / [ml],"1,257",47108,DB00619,Imatinib
,30594035,m/z,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3â394.2 for imatinib, m/z 480.3â394.2 for N-desmethyl imatinib, m/z 350.1â281.1 for voriconazole, m/z 366.1â224.1 for N-oxide voriconazole, and m/z 285.0â154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,350.1,49923,DB00619,Imatinib
,30594035,m/z,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3â394.2 for imatinib, m/z 480.3â394.2 for N-desmethyl imatinib, m/z 350.1â281.1 for voriconazole, m/z 366.1â224.1 for N-oxide voriconazole, and m/z 285.0â154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,281.1,49924,DB00619,Imatinib
,30594035,m/z,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3â394.2 for imatinib, m/z 480.3â394.2 for N-desmethyl imatinib, m/z 350.1â281.1 for voriconazole, m/z 366.1â224.1 for N-oxide voriconazole, and m/z 285.0â154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,366.1,49925,DB00619,Imatinib
,30594035,m/z,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3â394.2 for imatinib, m/z 480.3â394.2 for N-desmethyl imatinib, m/z 350.1â281.1 for voriconazole, m/z 366.1â224.1 for N-oxide voriconazole, and m/z 285.0â154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,224.1,49926,DB00619,Imatinib
,30594035,m,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3â394.2 for imatinib, m/z 480.3â394.2 for N-desmethyl imatinib, m/z 350.1â281.1 for voriconazole, m/z 366.1â224.1 for N-oxide voriconazole, and m/z 285.0â154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,285.0,49927,DB00619,Imatinib
,15073132,Peak plasma imatinib concentrations,Peak plasma imatinib concentrations ranged from 6.4 to 9.5 microM after i.v. dosing and 0.8 to 2.8 microM after p.o. dosing.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),Î¼M,6.4 to 9.5,50129,DB00619,Imatinib
,15073132,Peak plasma imatinib concentrations,Peak plasma imatinib concentrations ranged from 6.4 to 9.5 microM after i.v. dosing and 0.8 to 2.8 microM after p.o. dosing.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),Î¼M,0.8 to 2.8,50130,DB00619,Imatinib
,15073132,area under the plasma concentration versus time curve,"The mean +/-SD area under the plasma concentration versus time curve was 2480 +/-1340 microM.min and 1191 +/-146 microM.min after i.v. and p.o. dosing, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),minÂ·Î¼M,2480,50131,DB00619,Imatinib
,15073132,area under the plasma concentration versus time curve,"The mean +/-SD area under the plasma concentration versus time curve was 2480 +/-1340 microM.min and 1191 +/-146 microM.min after i.v. and p.o. dosing, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),minÂ·Î¼M,1191,50132,DB00619,Imatinib
,15073132,terminal half-life,The terminal half-life was 529 +/-167 min after i.v. dosing and 266 +/-88 min after p.o. dosing.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),min,529,50133,DB00619,Imatinib
,15073132,terminal half-life,The terminal half-life was 529 +/-167 min after i.v. dosing and 266 +/-88 min after p.o. dosing.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),min,266,50134,DB00619,Imatinib
,15073132,steady state volume of distribution,"After i.v. dosing the steady state volume of distribution was 5.9 +/-2.8 liter/kg, and the total body clearance was 12 +/-5 ml/min/kg.",Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),[l] / [kg],5.9,50135,DB00619,Imatinib
,15073132,total body clearance,"After i.v. dosing the steady state volume of distribution was 5.9 +/-2.8 liter/kg, and the total body clearance was 12 +/-5 ml/min/kg.",Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),[ml] / [kgÂ·min],12,50136,DB00619,Imatinib
,15073132,peak CSF concentration,The mean peak CSF concentration was 0.25 +/-0.07 microM after i.v. dosing and 0.07 +/-0.04 microM after p.o. dosing.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),Î¼M,0.25,50137,DB00619,Imatinib
,15073132,peak CSF concentration,The mean peak CSF concentration was 0.25 +/-0.07 microM after i.v. dosing and 0.07 +/-0.04 microM after p.o. dosing.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),Î¼M,0.07,50138,DB00619,Imatinib
,15073132,CSF:plasma area under the plasma concentration versus time curve ratio,The mean CSF:plasma area under the plasma concentration versus time curve ratio for all of the animals was 5% +/-2%.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),%,5,50139,DB00619,Imatinib
,34406581,trough,"Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2-34.5), 33.1 (21.2-40.3) and 27.7 (13.6-29.9) in patients 1, 2, and 3, respectively.",Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34406581/),[ng] / [ml],17.2,50813,DB00619,Imatinib
,34406581,trough,"Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2-34.5), 33.1 (21.2-40.3) and 27.7 (13.6-29.9) in patients 1, 2, and 3, respectively.",Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34406581/),[ng] / [ml],33.1,50814,DB00619,Imatinib
,34406581,trough,"Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2-34.5), 33.1 (21.2-40.3) and 27.7 (13.6-29.9) in patients 1, 2, and 3, respectively.",Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34406581/),[ng] / [ml],27.7,50815,DB00619,Imatinib
,22080802,flow rate,Chromatographic separation of the drugs is achieved on an RP-C(18) column at flow rate of 0.9 mL/min at 35Â°C; eluate is monitored at 267 nm.,A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ml] / [min],0.9,53637,DB00619,Imatinib
,22080802,extraction recovery,Mean intra-day and inter-day precision for all compounds are 2.5 and 13.3%; mean accuracy is 13.9%; extraction recovery ranges within 40.24 and 81.81%.,A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),%,40.24,53638,DB00619,Imatinib
,22080802,extraction recovery,Mean intra-day and inter-day precision for all compounds are 2.5 and 13.3%; mean accuracy is 13.9%; extraction recovery ranges within 40.24 and 81.81%.,A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),%,81.81,53639,DB00619,Imatinib
,22080802,Limits of detection,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],10,53640,DB00619,Imatinib
,22080802,Limits of detection,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],50,53641,DB00619,Imatinib
,22080802,limits of quantitation,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],50,53642,DB00619,Imatinib
,22080802,limits of quantitation,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],100,53643,DB00619,Imatinib
,20515524,flow rate,"Efficient chromatographic separation has been performed on a Zorbax Extend (5 microm, 4.6 x 250 mm) double end-capped C(18) column using a mobile phase consisting of methanol and aqueous triethyl amine (pH 10.5; 1%, v/v) (60:40, v/v) in an isocratic mode at a flow rate of 1 mL/min.",Validation of an HPLC method for determination of imatinib mesylate in rat serum and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515524/),[ml] / [min],1,55100,DB00619,Imatinib
,20515524,recoveries,Simple and effective liquid-liquid extraction technique has resulted in consistent and high recoveries (90.32-95.86%) at all concentrations studied.,Validation of an HPLC method for determination of imatinib mesylate in rat serum and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515524/),%,90.32-95.86,55101,DB00619,Imatinib
,16144928,DLT,"With the addition of ara-C, the DLT was reached at 540 microg/wk.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[Î¼g] / [wk],540,55567,DB00619,Imatinib
,16144928,serum peak concentration (C(max)),"The mean serum peak concentration (C(max)) of PEG-IFN increased from 9.4 to 28 ng/mL as the dose increased from 270 to 450 microg/wk, with no further increases in C(max) at higher dose levels.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[ng] / [ml],9.4,55568,DB00619,Imatinib
,16144928,serum peak concentration (C(max)),"The mean serum peak concentration (C(max)) of PEG-IFN increased from 9.4 to 28 ng/mL as the dose increased from 270 to 450 microg/wk, with no further increases in C(max) at higher dose levels.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[ng] / [ml],28,55569,DB00619,Imatinib
,16144928,area under the serum concentration-time curve (AUC),"The mean +/- SD area under the serum concentration-time curve (AUC) calculated after the first dose also increased from 1,022 +/- 694 to 3,343 +/- 2,728 ng hour/mL as dose was increased from 270 to 450 microg/wk, showing a dose-related increase in systemic exposure of PEG-IFN.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[hÂ·ng] / [ml],"1,022",55570,DB00619,Imatinib
,16144928,area under the serum concentration-time curve (AUC),"The mean +/- SD area under the serum concentration-time curve (AUC) calculated after the first dose also increased from 1,022 +/- 694 to 3,343 +/- 2,728 ng hour/mL as dose was increased from 270 to 450 microg/wk, showing a dose-related increase in systemic exposure of PEG-IFN.",Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144928/),[hÂ·ng] / [ml],"3,343",55571,DB00619,Imatinib
,23559824,total run time,The injection volume of 50 Î¼L and imatinib was monitored using UV detection 270 nm after a clean-up step with diethyl ether and with a total run time of 6 min.,Quantitative determination of imatinib stability under various stress conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23559824/),min,6,57528,DB00619,Imatinib
,23559824,limits of detection,"The limits of detection and quantitation of the method were 0.025 and 0.5 Î¼g/mL, respectively.",Quantitative determination of imatinib stability under various stress conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23559824/),[Î¼g] / [ml],0.025,57529,DB00619,Imatinib
,23559824,limits of detection,"The limits of detection and quantitation of the method were 0.025 and 0.5 Î¼g/mL, respectively.",Quantitative determination of imatinib stability under various stress conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23559824/),[Î¼g] / [ml],0.5,57530,DB00619,Imatinib
,27139217,flow rate,"After VA-DSPE, chromatographic separation was performed on an ACQUITY UPLC(Â®) BEH C18 column (2.1mmÃ100mm, 1.7Î¼m) with a 3min gradient elution using 0.1% formic acid and methanol as mobile phase at a flow rate of 0.3mL/min.",The metal-organic framework MIL-101(Cr) as efficient adsorbent in a vortex-assisted dispersive solid-phase extraction of imatinib mesylate in rat plasma coupled with ultra-performance liquid chromatography/mass spectrometry: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27139217/),[ml] / [min],0.3,57752,DB00619,Imatinib
higher,27139217,recovery,The lower limit of quantification of 1ng/mL was achieved and the mean recovery of the analyte was higher than 81.2%.,The metal-organic framework MIL-101(Cr) as efficient adsorbent in a vortex-assisted dispersive solid-phase extraction of imatinib mesylate in rat plasma coupled with ultra-performance liquid chromatography/mass spectrometry: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27139217/),%,81.2,57753,DB00619,Imatinib
,21635257,tissue-to-plasma AUC(0-â) ratio,"Metronidazole increased imatinib's tissue-to-plasma AUC(0-â) ratio in liver from 2.29 to 4.53 and in kidney from 3.04 to 7.57, suggesting higher uptake efficiency.","Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21635257/),,2.29 to 4.53,58838,DB00619,Imatinib
,21635257,tissue-to-plasma AUC(0-â) ratio,"Metronidazole increased imatinib's tissue-to-plasma AUC(0-â) ratio in liver from 2.29 to 4.53 and in kidney from 3.04 to 7.57, suggesting higher uptake efficiency.","Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21635257/),,3.04 to 7.57,58839,DB00619,Imatinib
,20608939,C(min),"The C(min) level was strongly associated with the achievement of MMR at the 12th month, and ROC analysis demonstrated C(min) levels and their discrimination potential for major molecular response (MMR) with the best sensitivity (63.2%) and specificity (68.2%) at a C(min) threshold of 974 ng/mL.",Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20608939/),[ng] / [ml],974,59787,DB00619,Imatinib
,20608939,C(min),These results collectively indicated that maintaining â¼1000 ng/mL of C(min) was clinically and biologically important for the optimal response in CML patients treated with imatinib.,Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20608939/),[ng] / [ml],â¼1000,59788,DB00619,Imatinib
,19088049,apparent oral clearance,"Mean +/- SD pharmacokinetic variables in smokers (n = 9) versus nonsmokers (n = 25) groups were 9.6 +/- 5.5 versus 9.2 +/- 4.6 L/h (apparent oral clearance), 216.5 +/- 114.3 versus 207.0 +/- 116.9 L (distribution volume), 16.1 +/- 6.0 versus 16.5 +/- 6.0 h (elimination half-life), and 133.6 +/- 71.0 versus 142.3 +/- 84.0 ng h/mL mg area under the concentration curve; P > 0.05.",Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088049/),[l] / [h],9.2,63827,DB00619,Imatinib
,19088049,distribution volume,"Mean +/- SD pharmacokinetic variables in smokers (n = 9) versus nonsmokers (n = 25) groups were 9.6 +/- 5.5 versus 9.2 +/- 4.6 L/h (apparent oral clearance), 216.5 +/- 114.3 versus 207.0 +/- 116.9 L (distribution volume), 16.1 +/- 6.0 versus 16.5 +/- 6.0 h (elimination half-life), and 133.6 +/- 71.0 versus 142.3 +/- 84.0 ng h/mL mg area under the concentration curve; P > 0.05.",Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088049/),l,207.0,63828,DB00619,Imatinib
,19088049,elimination half-life,"Mean +/- SD pharmacokinetic variables in smokers (n = 9) versus nonsmokers (n = 25) groups were 9.6 +/- 5.5 versus 9.2 +/- 4.6 L/h (apparent oral clearance), 216.5 +/- 114.3 versus 207.0 +/- 116.9 L (distribution volume), 16.1 +/- 6.0 versus 16.5 +/- 6.0 h (elimination half-life), and 133.6 +/- 71.0 versus 142.3 +/- 84.0 ng h/mL mg area under the concentration curve; P > 0.05.",Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088049/),h,16.5,63829,DB00619,Imatinib
,19088049,elimination half-life,"Mean +/- SD pharmacokinetic variables in smokers (n = 9) versus nonsmokers (n = 25) groups were 9.6 +/- 5.5 versus 9.2 +/- 4.6 L/h (apparent oral clearance), 216.5 +/- 114.3 versus 207.0 +/- 116.9 L (distribution volume), 16.1 +/- 6.0 versus 16.5 +/- 6.0 h (elimination half-life), and 133.6 +/- 71.0 versus 142.3 +/- 84.0 ng h/mL mg area under the concentration curve; P > 0.05.",Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088049/),[hÂ·ng] / [mgÂ·ml],142.3,63830,DB00619,Imatinib
,19088049,area under the concentration curve,"Mean +/- SD pharmacokinetic variables in smokers (n = 9) versus nonsmokers (n = 25) groups were 9.6 +/- 5.5 versus 9.2 +/- 4.6 L/h (apparent oral clearance), 216.5 +/- 114.3 versus 207.0 +/- 116.9 L (distribution volume), 16.1 +/- 6.0 versus 16.5 +/- 6.0 h (elimination half-life), and 133.6 +/- 71.0 versus 142.3 +/- 84.0 ng h/mL mg area under the concentration curve; P > 0.05.",Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088049/),[hÂ·ng] / [mgÂ·ml],133.6,63831,DB00619,Imatinib
,19088049,area under the concentration curve,"Mean +/- SD pharmacokinetic variables in smokers (n = 9) versus nonsmokers (n = 25) groups were 9.6 +/- 5.5 versus 9.2 +/- 4.6 L/h (apparent oral clearance), 216.5 +/- 114.3 versus 207.0 +/- 116.9 L (distribution volume), 16.1 +/- 6.0 versus 16.5 +/- 6.0 h (elimination half-life), and 133.6 +/- 71.0 versus 142.3 +/- 84.0 ng h/mL mg area under the concentration curve; P > 0.05.",Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088049/),[hÂ·ng] / [mgÂ·ml],142.3,63832,DB00619,Imatinib
,18359865,MTD,"The MTD of imatinib for patients concurrently receiving or not receiving EIAEDs was 1,000 mg.",Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359865/),mg,"1,000",67011,DB00619,Imatinib
,18359865,progression-free,"Among GBM patients with stable disease at enrollment (n=28), the median progression-free and overall survival times were 41.7 and 56.1 weeks, respectively.",Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359865/),weeks,41.7,67012,DB00619,Imatinib
,18359865,overall survival times,"Among GBM patients with stable disease at enrollment (n=28), the median progression-free and overall survival times were 41.7 and 56.1 weeks, respectively.",Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359865/),weeks,56.1,67013,DB00619,Imatinib
,16122278,absolute bioavailability,"Pharmacokinetic studies of imatinib in healthy volunteers and patients with CML, GIST and other cancers show that orally administered imatinib is well absorbed, and has an absolute bioavailability of 98% irrespective of oral dosage form (solution, capsule, tablet) or dosage strength (100 mg, 400 mg).",Clinical pharmacokinetics of imatinib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122278/),%,98,73700,DB00619,Imatinib
,16122278,terminal elimination half-life,The terminal elimination half-life is approximately 18 hours.,Clinical pharmacokinetics of imatinib. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122278/),h,18,73701,DB00619,Imatinib
,16122278,plasma concentrations,"Imatinib plasma concentrations predictably increase by 2- to 3-fold when reaching steady state with 400mg once-daily administration, to 2.6 +/- 0.8 microg/mL at peak and 1.2 +/- 0.8 microg/mL at trough, exceeding the 0.5 microg/mL (1 micromol/L) concentrations needed for tyrosine kinase inhibition in vitro and leading to normalisation of haematological parameters in the large majority of patients with CML irrespective of baseline white blood cell count.",Clinical pharmacokinetics of imatinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122278/),[Î¼g] / [ml],2,73702,DB00619,Imatinib
,16122278,peak,"Imatinib plasma concentrations predictably increase by 2- to 3-fold when reaching steady state with 400mg once-daily administration, to 2.6 +/- 0.8 microg/mL at peak and 1.2 +/- 0.8 microg/mL at trough, exceeding the 0.5 microg/mL (1 micromol/L) concentrations needed for tyrosine kinase inhibition in vitro and leading to normalisation of haematological parameters in the large majority of patients with CML irrespective of baseline white blood cell count.",Clinical pharmacokinetics of imatinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122278/),[Î¼g] / [ml],2,73703,DB00619,Imatinib
,16122278,trough,"Imatinib plasma concentrations predictably increase by 2- to 3-fold when reaching steady state with 400mg once-daily administration, to 2.6 +/- 0.8 microg/mL at peak and 1.2 +/- 0.8 microg/mL at trough, exceeding the 0.5 microg/mL (1 micromol/L) concentrations needed for tyrosine kinase inhibition in vitro and leading to normalisation of haematological parameters in the large majority of patients with CML irrespective of baseline white blood cell count.",Clinical pharmacokinetics of imatinib. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122278/),[Î¼g] / [ml],1.2,73704,DB00619,Imatinib
,16122278,faecal to urinary excretion ratio,The faecal to urinary excretion ratio is approximately 5:1.,Clinical pharmacokinetics of imatinib. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122278/),,5:1,73705,DB00619,Imatinib
,29803908,m,"Mass detection was carried out by electrospray ionization in the position mode, and the multiple reaction monitoring transitions were m/z 474.23 â 456.17 and m/z 494.30 â 394.20 for Enasidenib and imatinib, respectively.",Determination and pharmacokinetic study of Enasidenib in rat plasma by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29803908/),,474.23,76810,DB00619,Imatinib
,20523867,AUC(0-12),"Imatinib AUC(0-12) was 27.04 +/- 0.38 mg.h/ml, C(max) was 7.21 +/- 0.99 mg/ml and elimination half-life was 2.3 hours.",Reduced exposure of imatinib after coadministration with acetaminophen in mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523867/),[hÂ·mg] / [ml],27.04,78021,DB00619,Imatinib
,20523867,C(max),"Imatinib AUC(0-12) was 27.04 +/- 0.38 mg.h/ml, C(max) was 7.21 +/- 0.99 mg/ml and elimination half-life was 2.3 hours.",Reduced exposure of imatinib after coadministration with acetaminophen in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523867/),[mg] / [ml],7.21,78022,DB00619,Imatinib
,20523867,elimination half-life,"Imatinib AUC(0-12) was 27.04 +/- 0.38 mg.h/ml, C(max) was 7.21 +/- 0.99 mg/ml and elimination half-life was 2.3 hours.",Reduced exposure of imatinib after coadministration with acetaminophen in mice. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523867/),h,2.3,78023,DB00619,Imatinib
,20523867,half-life,"Acetaminophen affected the imatinib disposition profile: AUC(0-12) and C(max) decreased 56% and 59%, respectively and a longer half-life was observed (5.6 hours).",Reduced exposure of imatinib after coadministration with acetaminophen in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523867/),h,5.6,78024,DB00619,Imatinib
,26525154,flow rate,The three drugs were separated by high-performance liquid chromatography using a C18 column and an isocratic mobile phase running at a flow rate of 0.2 mL/min for 5 min.,"Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525154/),[ml] / [min],0.2,78501,DB00619,Imatinib
,19730279,k(e),"The percent deviation of C(t) at 3 hours before or after tau from C(min,std) will be 7.1%, 13.1%, and 23.4% for pts with low, typical, and high k(e) values, 0.023/hour, 0.041/hour, and 0.070/hour, respectively.",A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19730279/),1/[h],0.041,79557,DB00619,Imatinib
,19730279,k(e),"The percent deviation of C(t) at 3 hours before or after tau from C(min,std) will be 7.1%, 13.1%, and 23.4% for pts with low, typical, and high k(e) values, 0.023/hour, 0.041/hour, and 0.070/hour, respectively.",A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19730279/),1/[h],0.070,79558,DB00619,Imatinib
,19730279,k(e),"However, if a correction is made for C(t) by the algorithm using the typical k(e) value of 0.041 per hour, the percent deviation at 3 hours will be reduced to 5.3%, 0%, and 9.1% for pts with low, typical, and high k(e) values, respectively.",A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19730279/),1/[h],0.041,79559,DB00619,Imatinib
,34322850,zeta potential,"The nanoemulsion characteristics included particle size range of 60-80 nm, zeta potential of -6.6 to -7.8 mV, polydispersity index < 0.3, 3-day stability at 4 Â°C, and limited ImM leakage from the nanoemulsion in serum.",An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34322850/),mv,6.6 to -7.8,81535,DB00619,Imatinib
<,34322850,polydispersity index,"The nanoemulsion characteristics included particle size range of 60-80 nm, zeta potential of -6.6 to -7.8 mV, polydispersity index < 0.3, 3-day stability at 4 Â°C, and limited ImM leakage from the nanoemulsion in serum.",An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34322850/),,0.3,81536,DB00619,Imatinib
,17429625,systemic plasma clearance,"In vivo systemic plasma clearance values of dasatinib were 62, 26, 25, and 34 ml/min/kg in mouse, rat, dog, and monkey, respectively.",Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[ml] / [kgÂ·min],62,81997,DB00619,Imatinib
,17429625,systemic plasma clearance,"In vivo systemic plasma clearance values of dasatinib were 62, 26, 25, and 34 ml/min/kg in mouse, rat, dog, and monkey, respectively.",Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[ml] / [kgÂ·min],26,81998,DB00619,Imatinib
,17429625,systemic plasma clearance,"In vivo systemic plasma clearance values of dasatinib were 62, 26, 25, and 34 ml/min/kg in mouse, rat, dog, and monkey, respectively.",Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[ml] / [kgÂ·min],25,81999,DB00619,Imatinib
,17429625,systemic plasma clearance,"In vivo systemic plasma clearance values of dasatinib were 62, 26, 25, and 34 ml/min/kg in mouse, rat, dog, and monkey, respectively.",Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[ml] / [kgÂ·min],34,82000,DB00619,Imatinib
,17429625,Percent distribution,Percent distribution in blood cells ranged from 43% in mouse to 57% in dog.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,43,82001,DB00619,Imatinib
,17429625,Percent distribution,Percent distribution in blood cells ranged from 43% in mouse to 57% in dog.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,57,82002,DB00619,Imatinib
>,17429625,volumes of distribution,Dasatinib showed high volumes of distribution (>3 l/kg) and high serum protein binding values (>90%) in all four species tested.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[l] / [kg],3,82003,DB00619,Imatinib
>,17429625,serum protein binding,Dasatinib showed high volumes of distribution (>3 l/kg) and high serum protein binding values (>90%) in all four species tested.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,90,82004,DB00619,Imatinib
,17429625,Oral bioavailability,Oral bioavailability of dasatinib ranged from 14% in the mouse to 34% in the dog.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,14,82005,DB00619,Imatinib
,17429625,Oral bioavailability,Oral bioavailability of dasatinib ranged from 14% in the mouse to 34% in the dog.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,34,82006,DB00619,Imatinib
,15132131,Tmax,Median Tmax was 2.5 h for capsules and tablets.,"Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),h,2.5,86257,DB00619,Imatinib
,15132131,AUC((0-inf)),"Mean AUC((0-inf)) values were 27,094, 26,081 and 25,464 ng.h/ml for 4 x 100-mg capsules, 4 x 100-mg tablets, and 1 x 400-mg tablets, respectively.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),[hÂ·ng] / [ml],"27,094",86258,DB00619,Imatinib
,15132131,AUC((0-inf)),"Mean AUC((0-inf)) values were 27,094, 26,081 and 25,464 ng.h/ml for 4 x 100-mg capsules, 4 x 100-mg tablets, and 1 x 400-mg tablets, respectively.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),[hÂ·ng] / [ml],"26,081",86259,DB00619,Imatinib
,15132131,AUC((0-inf)),"Mean AUC((0-inf)) values were 27,094, 26,081 and 25,464 ng.h/ml for 4 x 100-mg capsules, 4 x 100-mg tablets, and 1 x 400-mg tablets, respectively.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),[hÂ·ng] / [ml],"25,464",86260,DB00619,Imatinib
,15132131,Cmax,"Cmax values were 1748, 1638 and 1606 ng/ml, and t(1/2) values were 15.8, 15.9 and 15.7 h.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),[ng] / [ml],1748,86261,DB00619,Imatinib
,15132131,Cmax,"Cmax values were 1748, 1638 and 1606 ng/ml, and t(1/2) values were 15.8, 15.9 and 15.7 h.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),[ng] / [ml],1638,86262,DB00619,Imatinib
,15132131,Cmax,"Cmax values were 1748, 1638 and 1606 ng/ml, and t(1/2) values were 15.8, 15.9 and 15.7 h.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),[ng] / [ml],1606,86263,DB00619,Imatinib
,15132131,t(1/2),"Cmax values were 1748, 1638 and 1606 ng/ml, and t(1/2) values were 15.8, 15.9 and 15.7 h.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),h,15.8,86264,DB00619,Imatinib
,15132131,t(1/2),"Cmax values were 1748, 1638 and 1606 ng/ml, and t(1/2) values were 15.8, 15.9 and 15.7 h.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),h,15.9,86265,DB00619,Imatinib
,15132131,t(1/2),"Cmax values were 1748, 1638 and 1606 ng/ml, and t(1/2) values were 15.8, 15.9 and 15.7 h.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),h,15.7,86266,DB00619,Imatinib
,15883819,maximum concentration,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),[ng] / [ml],"3,340",87590,DB00619,Imatinib
,15883819,maximum concentration,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),[ng] / [ml],781,87591,DB00619,Imatinib
,15883819,time to maximum concentration,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),h,2,87592,DB00619,Imatinib
,15883819,half-life,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),h,18.2,87593,DB00619,Imatinib
,15883819,half-life,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),h,34.0,87594,DB00619,Imatinib
,15883819,area under the curve,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),[hÂ·Î¼g] / [ml],53.9,87595,DB00619,Imatinib
,15883819,area under the curve,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),[hÂ·Î¼g] / [ml],14.8,87596,DB00619,Imatinib
,15883819,trough concentration,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),[ng] / [ml],"1,540",87597,DB00619,Imatinib
,15883819,trough concentration,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),[ng] / [ml],508,87598,DB00619,Imatinib
,21184622,C(max),"Mean Â± SD serum nilotinib C(max) was 1872 Â± 560 ng/mL, which is comparable to steady-state C(max) in CML and gastrointestinal stromal tumour patients receiving twice-daily 400 mg doses.","Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21184622/),[ng] / [ml],1872,92199,DB00619,Imatinib
,21311410,clearance,"Approximately 4.6-fold variability in individual clearance was observed (range, 3.4-15.5 L/hr).",Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311410/),[l] / [h],3.4-15.5,95761,DB00619,Imatinib
,21311410,clearance,"The individual estimated clearance was significantly increased in patients with the SLCO1B3 334GG genotype (median value Â± standard deviation, 9.5 Â± 3.1 L/hr; n = 19) compared with SLCO1B3 334TT and TG genotypes (7.0 Â± 3.1 L/hr; n = 15) (P = 0.019).",Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311410/),[l] / [h],9.5,95762,DB00619,Imatinib
,21311410,clearance,"The individual estimated clearance was significantly increased in patients with the SLCO1B3 334GG genotype (median value Â± standard deviation, 9.5 Â± 3.1 L/hr; n = 19) compared with SLCO1B3 334TT and TG genotypes (7.0 Â± 3.1 L/hr; n = 15) (P = 0.019).",Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311410/),[l] / [h],7.0,95763,DB00619,Imatinib
,21311410,clearance,Patients with the ABCB1 3435CC genotype had significantly higher imatinib clearance (12.7 Â± 3.0 L/hr; n = 7) compared with patients with ABCB1 3435CT and TT genotypes (7.9 Â± 2.7 L/hr; n = 27) (P = 0.035).,Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311410/),[l] / [h],12.7,95764,DB00619,Imatinib
,21311410,clearance,Patients with the ABCB1 3435CC genotype had significantly higher imatinib clearance (12.7 Â± 3.0 L/hr; n = 7) compared with patients with ABCB1 3435CT and TT genotypes (7.9 Â± 2.7 L/hr; n = 27) (P = 0.035).,Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311410/),[l] / [h],7.9,95765,DB00619,Imatinib
,20110053,t(1/2),"The mean (SD) t(1/2) was 15.1 (4.97) and 16.0 (9.13) hours in the mild-impairment and control groups, respectively, but was 21.6 (7.77) and 32.4 (10.7) hours in the moderate- and severe-impairment groups, respectively, reflecting the decrease in CL/F and/or increase in Vz/F in the latter 2 groups.","Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110053/),h,15.1,95914,DB00619,Imatinib
,20110053,t(1/2),"The mean (SD) t(1/2) was 15.1 (4.97) and 16.0 (9.13) hours in the mild-impairment and control groups, respectively, but was 21.6 (7.77) and 32.4 (10.7) hours in the moderate- and severe-impairment groups, respectively, reflecting the decrease in CL/F and/or increase in Vz/F in the latter 2 groups.","Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110053/),h,16.0,95915,DB00619,Imatinib
,20110053,t(1/2),"The mean (SD) t(1/2) was 15.1 (4.97) and 16.0 (9.13) hours in the mild-impairment and control groups, respectively, but was 21.6 (7.77) and 32.4 (10.7) hours in the moderate- and severe-impairment groups, respectively, reflecting the decrease in CL/F and/or increase in Vz/F in the latter 2 groups.","Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110053/),h,21.6,95916,DB00619,Imatinib
,20110053,t(1/2),"The mean (SD) t(1/2) was 15.1 (4.97) and 16.0 (9.13) hours in the mild-impairment and control groups, respectively, but was 21.6 (7.77) and 32.4 (10.7) hours in the moderate- and severe-impairment groups, respectively, reflecting the decrease in CL/F and/or increase in Vz/F in the latter 2 groups.","Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110053/),h,32.4,95917,DB00619,Imatinib
,16319507,time to treatment failure,Median time to treatment failure was 1.8 months in the whole study cohort and 3.7 months in the patients with stable disease.,Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16319507/),month,1.8,97341,DB00619,Imatinib
,16319507,time to treatment failure,Median time to treatment failure was 1.8 months in the whole study cohort and 3.7 months in the patients with stable disease.,Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16319507/),month,3.7,97342,DB00619,Imatinib
,18235115,dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)),"After the first imatinib dose, the mean (+/- SD) dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)) were 162 +/- 155, 171 +/- 72, 182 +/- 157, and 185 +/- 172 (mug/mL x h)/mg for normal, mild, moderate, and severe LD groups, respectively.",Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18235115/),[Î¼g] / [h)Â·mgÂ·ml],162,97956,DB00619,Imatinib
,18235115,dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)),"After the first imatinib dose, the mean (+/- SD) dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)) were 162 +/- 155, 171 +/- 72, 182 +/- 157, and 185 +/- 172 (mug/mL x h)/mg for normal, mild, moderate, and severe LD groups, respectively.",Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18235115/),[Î¼g] / [h)Â·mgÂ·ml],171,97957,DB00619,Imatinib
,18235115,dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)),"After the first imatinib dose, the mean (+/- SD) dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)) were 162 +/- 155, 171 +/- 72, 182 +/- 157, and 185 +/- 172 (mug/mL x h)/mg for normal, mild, moderate, and severe LD groups, respectively.",Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18235115/),[Î¼g] / [h)Â·mgÂ·ml],182,97958,DB00619,Imatinib
,18235115,dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)),"After the first imatinib dose, the mean (+/- SD) dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)) were 162 +/- 155, 171 +/- 72, 182 +/- 157, and 185 +/- 172 (mug/mL x h)/mg for normal, mild, moderate, and severe LD groups, respectively.",Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18235115/),[Î¼g] / [h)Â·mgÂ·ml],185,97959,DB00619,Imatinib
,25581063,apparent clearance (CL/F),"The population mean estimates of apparent clearance (CL/F) and volume (V/F) were 10.8 l h(-1) (95% CI 9.2, 12.4 l h(-1) ) and 267 l (95% CI 208, 326 l), respectively.","Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581063/),[l] / [h],10.8,100930,DB00619,Imatinib
,25581063,volume (V/F),"The population mean estimates of apparent clearance (CL/F) and volume (V/F) were 10.8 l h(-1) (95% CI 9.2, 12.4 l h(-1) ) and 267 l (95% CI 208, 326 l), respectively.","Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581063/),l,267,100931,DB00619,Imatinib
,19740393,area under the plasma concentration vs time curve (AUC),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[hÂ·Î¼g] / [ml],34.1,102887,DB00619,Imatinib
,19740393,area under the plasma concentration vs time curve (AUC),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[hÂ·Î¼g] / [ml],33.1,102888,DB00619,Imatinib
,19740393,maximum plasma concentration (C(max)),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[Î¼g] / [ml],2.04,102889,DB00619,Imatinib
,19740393,maximum plasma concentration (C(max)),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[Î¼g] / [ml],2.02,102890,DB00619,Imatinib
,19740393,half-life,"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),h,13.4,102891,DB00619,Imatinib
,19740393,half-life,"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),h,14.1,102892,DB00619,Imatinib
,21474977,plasma threshold level,"Because of the variability in imatinib exposure among patients, therapeutic drug monitoring to maintain a plasma threshold level of about 1,000 ng/ml would be beneficial during imatinib therapy.",Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21474977/),[ng] / [ml],"1,000",102952,DB00619,Imatinib
,21474977,trough level,"For CML patients who have an imatinib trough level of 1,000 ng/ml but lack a sufficient clinical response, switching to another tyrosine kinase inhibitor is recommended.",Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21474977/),[ng] / [ml],"1,000",102953,DB00619,Imatinib
,20016370,minimum therapeutic IM concentration,"In addition to the pharmacodynamic interest of this treatment, we found that the combined treatment significantly increased the IM Cmax (P<0.05) and significantly increased the IM trough concentration (C(24 h)) (P<0.01), which was always above the minimum therapeutic IM concentration (1 mumol/l) in plasma.","Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20016370/),[Î¼M] / [l],1,108176,DB00619,Imatinib
,32764164,C m i n â $,"The mean imatinib and nilotinib C m i n â ${C}_{min}\hat{\infty }$ were 1,065.46 Â± 765.71 and 1,445 Â± 1,010.35 ng/mL respectively.",Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32764164/),[ng] / [ml],"1,065.46",109669,DB00619,Imatinib
,32764164,C m i n â $,"The mean imatinib and nilotinib C m i n â ${C}_{min}\hat{\infty }$ were 1,065.46 Â± 765.71 and 1,445 Â± 1,010.35 ng/mL respectively.",Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32764164/),[ng] / [ml],"1,445",109670,DB00619,Imatinib
â¥,32764164,C m i n â $,"Half of the patients in each group were found to reach C m i n â ${C}_{min}\hat{\infty }$ target (â¥1.000 ng/mL, imatinib; â¥800 ng/mL nilotinib), but only 12 (35,29%) of them result in BCR-ABL ratio â¤0.1%.",Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32764164/),[ng] / [ml],1.000,109671,DB00619,Imatinib
â¥,32764164,C m i n â $,"Half of the patients in each group were found to reach C m i n â ${C}_{min}\hat{\infty }$ target (â¥1.000 ng/mL, imatinib; â¥800 ng/mL nilotinib), but only 12 (35,29%) of them result in BCR-ABL ratio â¤0.1%.",Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32764164/),[ng] / [m],800,109672,DB00619,Imatinib
,15470331,clearance,"St John's wort administration increased imatinib clearance by 43% ( P < .001), from 12.5 +/- 3.6 L/h to 17.9 +/- 5.6 L/h; imatinib area under the concentration versus time curve (AUC) extrapolated to infinity was decreased by 30%, from 34.5 +/- 9.5 microg . h/mL to 24.2 +/- 7.0 microg . h/mL ( P < .001).",Effect of St John's wort on imatinib mesylate pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[l] / [h],12.5,110451,DB00619,Imatinib
,15470331,clearance,"St John's wort administration increased imatinib clearance by 43% ( P < .001), from 12.5 +/- 3.6 L/h to 17.9 +/- 5.6 L/h; imatinib area under the concentration versus time curve (AUC) extrapolated to infinity was decreased by 30%, from 34.5 +/- 9.5 microg . h/mL to 24.2 +/- 7.0 microg . h/mL ( P < .001).",Effect of St John's wort on imatinib mesylate pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[l] / [h],17.9,110452,DB00619,Imatinib
,15470331,area under the concentration versus time curve (AUC),"St John's wort administration increased imatinib clearance by 43% ( P < .001), from 12.5 +/- 3.6 L/h to 17.9 +/- 5.6 L/h; imatinib area under the concentration versus time curve (AUC) extrapolated to infinity was decreased by 30%, from 34.5 +/- 9.5 microg . h/mL to 24.2 +/- 7.0 microg . h/mL ( P < .001).",Effect of St John's wort on imatinib mesylate pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[hÂ·Î¼g] / [ml],34.5,110453,DB00619,Imatinib
,15470331,area under the concentration versus time curve (AUC),"St John's wort administration increased imatinib clearance by 43% ( P < .001), from 12.5 +/- 3.6 L/h to 17.9 +/- 5.6 L/h; imatinib area under the concentration versus time curve (AUC) extrapolated to infinity was decreased by 30%, from 34.5 +/- 9.5 microg . h/mL to 24.2 +/- 7.0 microg . h/mL ( P < .001).",Effect of St John's wort on imatinib mesylate pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[hÂ·Î¼g] / [ml],24.2,110454,DB00619,Imatinib
,15470331,half-life,Imatinib half-life (12.8 hours versus 9.0 hours) and maximum concentration (C max ) (2.2 microg/mL versus 1.8 microg/mL) were also significantly decreased ( P < .005).,Effect of St John's wort on imatinib mesylate pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),h,12.8,110455,DB00619,Imatinib
,15470331,half-life,Imatinib half-life (12.8 hours versus 9.0 hours) and maximum concentration (C max ) (2.2 microg/mL versus 1.8 microg/mL) were also significantly decreased ( P < .005).,Effect of St John's wort on imatinib mesylate pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),h,9.0,110456,DB00619,Imatinib
,15470331,maximum concentration (C max ),Imatinib half-life (12.8 hours versus 9.0 hours) and maximum concentration (C max ) (2.2 microg/mL versus 1.8 microg/mL) were also significantly decreased ( P < .005).,Effect of St John's wort on imatinib mesylate pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[Î¼g] / [ml],2.2,110457,DB00619,Imatinib
,15470331,maximum concentration (C max ),Imatinib half-life (12.8 hours versus 9.0 hours) and maximum concentration (C max ) (2.2 microg/mL versus 1.8 microg/mL) were also significantly decreased ( P < .005).,Effect of St John's wort on imatinib mesylate pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[Î¼g] / [ml],1.8,110458,DB00619,Imatinib
,15470331,C max,"N -desmethyl-imatinib C max was increased from 285 +/- 95 ng/mL to 318 +/- 95 ng/mL during St John's wort dosing, but the AUC from 0 to 72 hours was not altered.",Effect of St John's wort on imatinib mesylate pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[ng] / [ml],285,110459,DB00619,Imatinib
,15470331,C max,"N -desmethyl-imatinib C max was increased from 285 +/- 95 ng/mL to 318 +/- 95 ng/mL during St John's wort dosing, but the AUC from 0 to 72 hours was not altered.",Effect of St John's wort on imatinib mesylate pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[ng] / [ml],318,110460,DB00619,Imatinib
,29032042,retention time,"No endogenous interfering compounds was discovered at retention time of brigatinib (0.56min) and imatinib (IS, 1.41min).",A reliable and stable method for determination of brigatinib in rat plasma by UPLC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032042/),min,0.56,118515,DB00619,Imatinib
,29032042,retention time,"No endogenous interfering compounds was discovered at retention time of brigatinib (0.56min) and imatinib (IS, 1.41min).",A reliable and stable method for determination of brigatinib in rat plasma by UPLC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032042/),min,1.41,118516,DB00619,Imatinib
,29032042,m/z,"And the MRM transitions were m/z 584.09â484.08 and m/z 494.3â394.2 for brigatinib and IS, respectively.",A reliable and stable method for determination of brigatinib in rat plasma by UPLC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032042/),,584.09,118517,DB00619,Imatinib
,29032042,m/z,"And the MRM transitions were m/z 584.09â484.08 and m/z 494.3â394.2 for brigatinib and IS, respectively.",A reliable and stable method for determination of brigatinib in rat plasma by UPLC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032042/),,484.08,118518,DB00619,Imatinib
,29032042,m/z,"And the MRM transitions were m/z 584.09â484.08 and m/z 494.3â394.2 for brigatinib and IS, respectively.",A reliable and stable method for determination of brigatinib in rat plasma by UPLC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032042/),,494.3,118519,DB00619,Imatinib
,29032042,m/z,"And the MRM transitions were m/z 584.09â484.08 and m/z 494.3â394.2 for brigatinib and IS, respectively.",A reliable and stable method for determination of brigatinib in rat plasma by UPLC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032042/),,394.2,118520,DB00619,Imatinib
,29032042,recovery,The recovery of brigatinib was from 85.26% to 96.05%.,A reliable and stable method for determination of brigatinib in rat plasma by UPLC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032042/),%,85.26,118521,DB00619,Imatinib
,29032042,recovery,The recovery of brigatinib was from 85.26% to 96.05%.,A reliable and stable method for determination of brigatinib in rat plasma by UPLC-MS/MS: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032042/),%,96.05,118522,DB00619,Imatinib
,27995880,Cmax,"The major pharmacokinetic parameters were as follows: Cmax (209.01Â±58.69) Î¼g/L and (223.07Â±79.51) Î¼g/L, Tmax (1.1Â±0.8) h and (1.1Â±0.8) h, T1/2 (5.10Â±1.34) h and (4.39Â±0.74) h, AUC0-Ï (646.65Â±185.67) hÂ·Î¼g/L and (695.84Â±273.40) hÂ·Î¼g/L (all P>0.05); AUC0-â (668.11Â±186.00) hÂ·Î¼g/L and (712.42Â±278.08) hÂ·Î¼g/L, MRT (5.32 Â± 1.70) h and (4.68 Â± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[Î¼g] / [l],209.01,121364,DB00619,Imatinib
,27995880,Cmax,"The major pharmacokinetic parameters were as follows: Cmax (209.01Â±58.69) Î¼g/L and (223.07Â±79.51) Î¼g/L, Tmax (1.1Â±0.8) h and (1.1Â±0.8) h, T1/2 (5.10Â±1.34) h and (4.39Â±0.74) h, AUC0-Ï (646.65Â±185.67) hÂ·Î¼g/L and (695.84Â±273.40) hÂ·Î¼g/L (all P>0.05); AUC0-â (668.11Â±186.00) hÂ·Î¼g/L and (712.42Â±278.08) hÂ·Î¼g/L, MRT (5.32 Â± 1.70) h and (4.68 Â± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[Î¼g] / [l],223.07,121365,DB00619,Imatinib
,27995880,Tmax,"The major pharmacokinetic parameters were as follows: Cmax (209.01Â±58.69) Î¼g/L and (223.07Â±79.51) Î¼g/L, Tmax (1.1Â±0.8) h and (1.1Â±0.8) h, T1/2 (5.10Â±1.34) h and (4.39Â±0.74) h, AUC0-Ï (646.65Â±185.67) hÂ·Î¼g/L and (695.84Â±273.40) hÂ·Î¼g/L (all P>0.05); AUC0-â (668.11Â±186.00) hÂ·Î¼g/L and (712.42Â±278.08) hÂ·Î¼g/L, MRT (5.32 Â± 1.70) h and (4.68 Â± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,1.1,121366,DB00619,Imatinib
,27995880,T1/2,"The major pharmacokinetic parameters were as follows: Cmax (209.01Â±58.69) Î¼g/L and (223.07Â±79.51) Î¼g/L, Tmax (1.1Â±0.8) h and (1.1Â±0.8) h, T1/2 (5.10Â±1.34) h and (4.39Â±0.74) h, AUC0-Ï (646.65Â±185.67) hÂ·Î¼g/L and (695.84Â±273.40) hÂ·Î¼g/L (all P>0.05); AUC0-â (668.11Â±186.00) hÂ·Î¼g/L and (712.42Â±278.08) hÂ·Î¼g/L, MRT (5.32 Â± 1.70) h and (4.68 Â± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,5.10,121367,DB00619,Imatinib
,27995880,T1/2,"The major pharmacokinetic parameters were as follows: Cmax (209.01Â±58.69) Î¼g/L and (223.07Â±79.51) Î¼g/L, Tmax (1.1Â±0.8) h and (1.1Â±0.8) h, T1/2 (5.10Â±1.34) h and (4.39Â±0.74) h, AUC0-Ï (646.65Â±185.67) hÂ·Î¼g/L and (695.84Â±273.40) hÂ·Î¼g/L (all P>0.05); AUC0-â (668.11Â±186.00) hÂ·Î¼g/L and (712.42Â±278.08) hÂ·Î¼g/L, MRT (5.32 Â± 1.70) h and (4.68 Â± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,4.39,121368,DB00619,Imatinib
,27995880,AUC0-Ï,"The major pharmacokinetic parameters were as follows: Cmax (209.01Â±58.69) Î¼g/L and (223.07Â±79.51) Î¼g/L, Tmax (1.1Â±0.8) h and (1.1Â±0.8) h, T1/2 (5.10Â±1.34) h and (4.39Â±0.74) h, AUC0-Ï (646.65Â±185.67) hÂ·Î¼g/L and (695.84Â±273.40) hÂ·Î¼g/L (all P>0.05); AUC0-â (668.11Â±186.00) hÂ·Î¼g/L and (712.42Â±278.08) hÂ·Î¼g/L, MRT (5.32 Â± 1.70) h and (4.68 Â± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[hÂ·Î¼g] / [l],646.65,121369,DB00619,Imatinib
,27995880,AUC0-Ï,"The major pharmacokinetic parameters were as follows: Cmax (209.01Â±58.69) Î¼g/L and (223.07Â±79.51) Î¼g/L, Tmax (1.1Â±0.8) h and (1.1Â±0.8) h, T1/2 (5.10Â±1.34) h and (4.39Â±0.74) h, AUC0-Ï (646.65Â±185.67) hÂ·Î¼g/L and (695.84Â±273.40) hÂ·Î¼g/L (all P>0.05); AUC0-â (668.11Â±186.00) hÂ·Î¼g/L and (712.42Â±278.08) hÂ·Î¼g/L, MRT (5.32 Â± 1.70) h and (4.68 Â± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[hÂ·Î¼g] / [l],695.84,121370,DB00619,Imatinib
,27995880,AUC0-â,"The major pharmacokinetic parameters were as follows: Cmax (209.01Â±58.69) Î¼g/L and (223.07Â±79.51) Î¼g/L, Tmax (1.1Â±0.8) h and (1.1Â±0.8) h, T1/2 (5.10Â±1.34) h and (4.39Â±0.74) h, AUC0-Ï (646.65Â±185.67) hÂ·Î¼g/L and (695.84Â±273.40) hÂ·Î¼g/L (all P>0.05); AUC0-â (668.11Â±186.00) hÂ·Î¼g/L and (712.42Â±278.08) hÂ·Î¼g/L, MRT (5.32 Â± 1.70) h and (4.68 Â± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[hÂ·Î¼g] / [l],668.11,121371,DB00619,Imatinib
,27995880,AUC0-â,"The major pharmacokinetic parameters were as follows: Cmax (209.01Â±58.69) Î¼g/L and (223.07Â±79.51) Î¼g/L, Tmax (1.1Â±0.8) h and (1.1Â±0.8) h, T1/2 (5.10Â±1.34) h and (4.39Â±0.74) h, AUC0-Ï (646.65Â±185.67) hÂ·Î¼g/L and (695.84Â±273.40) hÂ·Î¼g/L (all P>0.05); AUC0-â (668.11Â±186.00) hÂ·Î¼g/L and (712.42Â±278.08) hÂ·Î¼g/L, MRT (5.32 Â± 1.70) h and (4.68 Â± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[hÂ·Î¼g] / [l],712.42,121372,DB00619,Imatinib
,27995880,MRT,"The major pharmacokinetic parameters were as follows: Cmax (209.01Â±58.69) Î¼g/L and (223.07Â±79.51) Î¼g/L, Tmax (1.1Â±0.8) h and (1.1Â±0.8) h, T1/2 (5.10Â±1.34) h and (4.39Â±0.74) h, AUC0-Ï (646.65Â±185.67) hÂ·Î¼g/L and (695.84Â±273.40) hÂ·Î¼g/L (all P>0.05); AUC0-â (668.11Â±186.00) hÂ·Î¼g/L and (712.42Â±278.08) hÂ·Î¼g/L, MRT (5.32 Â± 1.70) h and (4.68 Â± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,5.32,121373,DB00619,Imatinib
,27995880,MRT,"The major pharmacokinetic parameters were as follows: Cmax (209.01Â±58.69) Î¼g/L and (223.07Â±79.51) Î¼g/L, Tmax (1.1Â±0.8) h and (1.1Â±0.8) h, T1/2 (5.10Â±1.34) h and (4.39Â±0.74) h, AUC0-Ï (646.65Â±185.67) hÂ·Î¼g/L and (695.84Â±273.40) hÂ·Î¼g/L (all P>0.05); AUC0-â (668.11Â±186.00) hÂ·Î¼g/L and (712.42Â±278.08) hÂ·Î¼g/L, MRT (5.32 Â± 1.70) h and (4.68 Â± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,4.68,121374,DB00619,Imatinib
,21350820,steady-state im,"Mean Â± standard deviation steady-state imatinib trough concentration (2.6 Â± 1.2 Î¼g/ml) was approximately 2.6-fold higher than previously observed in other cancer populations, and likely contributed to the poor tolerability of the combination in MBC.",Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350820/),[Î¼g] / [ml],2.6,122566,DB00619,Imatinib
,21350820,trough concentration,"Mean Â± standard deviation steady-state imatinib trough concentration (2.6 Â± 1.2 Î¼g/ml) was approximately 2.6-fold higher than previously observed in other cancer populations, and likely contributed to the poor tolerability of the combination in MBC.",Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350820/),[Î¼g] / [ml],2.6,122567,DB00619,Imatinib
,20054526,metabolic ratio,"Patients that achieved complete molecular response showed significantly (Mann-Whitney U-test, p=0.013) higher in vivo CYP3A activity (median quinine metabolic ratio = 10.1) than patients achieving partial molecular response (median = 15.9).",CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20054526/),,10.1,122997,DB00619,Imatinib
,19698017,plasma half-life,"The agent, administered orally, has approximately 98% oral bioavailability, achieves maximum plasma concentration approximately 2-4 hours after ingestion, and has a plasma half-life of approximately 18 hours.",Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698017/),h,18,123857,DB00619,Imatinib
,19698017,trough plasma concentration,"The patient's trough plasma concentration before surgery (1558 ng/ml) was consistent with those found in the literature (>/= 1000 ng/ml), whereas her trough concentrations after surgery were 46-60% lower (629-836 ng/ml) than the preoperative value.",Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698017/),[ng] / [ml],1558,123858,DB00619,Imatinib
,19698017,trough concentrations,"The patient's trough plasma concentration before surgery (1558 ng/ml) was consistent with those found in the literature (>/= 1000 ng/ml), whereas her trough concentrations after surgery were 46-60% lower (629-836 ng/ml) than the preoperative value.",Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698017/),[ng] / [ml],629-836,123859,DB00619,Imatinib
,24170263,area under the plasma concentration versus time curve (AUC),"Calcium carbonate administration did not significantly affect the imatinib area under the plasma concentration versus time curve (AUC) (41.2 Î¼g/mL h alone vs. 40.8 Î¼g/mL h with calcium carbonate, P = 0.99), maximum plasma concentration (C(max)) (2.35 Î¼g/mL alone vs. 2.39 Î¼g/mL with calcium carbonate, P = 0.89).",Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170263/),[Î¼g] / [hÂ·ml],41.2,127162,DB00619,Imatinib
,24170263,area under the plasma concentration versus time curve (AUC),"Calcium carbonate administration did not significantly affect the imatinib area under the plasma concentration versus time curve (AUC) (41.2 Î¼g/mL h alone vs. 40.8 Î¼g/mL h with calcium carbonate, P = 0.99), maximum plasma concentration (C(max)) (2.35 Î¼g/mL alone vs. 2.39 Î¼g/mL with calcium carbonate, P = 0.89).",Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170263/),[Î¼g] / [hÂ·ml],40.8,127163,DB00619,Imatinib
,24170263,maximum plasma concentration (C(max)),"Calcium carbonate administration did not significantly affect the imatinib area under the plasma concentration versus time curve (AUC) (41.2 Î¼g/mL h alone vs. 40.8 Î¼g/mL h with calcium carbonate, P = 0.99), maximum plasma concentration (C(max)) (2.35 Î¼g/mL alone vs. 2.39 Î¼g/mL with calcium carbonate, P = 0.89).",Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170263/),[Î¼g] / [ml],2.35,127164,DB00619,Imatinib
,24170263,maximum plasma concentration (C(max)),"Calcium carbonate administration did not significantly affect the imatinib area under the plasma concentration versus time curve (AUC) (41.2 Î¼g/mL h alone vs. 40.8 Î¼g/mL h with calcium carbonate, P = 0.99), maximum plasma concentration (C(max)) (2.35 Î¼g/mL alone vs. 2.39 Î¼g/mL with calcium carbonate, P = 0.89).",Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170263/),[Î¼g] / [ml],2.39,127165,DB00619,Imatinib
,23014737,time to progression,Five patients (13.2 %) had a partial response (PR) and 13 patients (34.2 %) had SD; the average time to progression in those with clinical benefit was 17 weeks (range: 7-28 weeks).,A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23014737/),weeks,17,130633,DB00619,Imatinib
,25939551,particle size (Sz),"The optimized IMT-NLC exhibited a particle size (Sz) of 148.80 Â± 1.37 nm, polydispersity index (PDI) 0.191 Â± 0.017 of and Î¶-potential of -23.0 Â± 1.5 mV, with a drug loading (DL) of 5.48 Â± 0.01% and encapsulation efficiency (EE) of 97.93 Â± 0.03%.",Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939551/),nm,148.80,132046,DB00619,Imatinib
,25939551,polydispersity index (PDI),"The optimized IMT-NLC exhibited a particle size (Sz) of 148.80 Â± 1.37 nm, polydispersity index (PDI) 0.191 Â± 0.017 of and Î¶-potential of -23.0 Â± 1.5 mV, with a drug loading (DL) of 5.48 Â± 0.01% and encapsulation efficiency (EE) of 97.93 Â± 0.03%.",Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939551/),,0.191,132047,DB00619,Imatinib
,25939551,Î¶-potential,"The optimized IMT-NLC exhibited a particle size (Sz) of 148.80 Â± 1.37 nm, polydispersity index (PDI) 0.191 Â± 0.017 of and Î¶-potential of -23.0 Â± 1.5 mV, with a drug loading (DL) of 5.48 Â± 0.01% and encapsulation efficiency (EE) of 97.93 Â± 0.03%.",Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939551/),m,-,132048,DB00619,Imatinib
,25939551,Î¶-potential,"The optimized IMT-NLC exhibited a particle size (Sz) of 148.80 Â± 1.37 nm, polydispersity index (PDI) 0.191 Â± 0.017 of and Î¶-potential of -23.0 Â± 1.5 mV, with a drug loading (DL) of 5.48 Â± 0.01% and encapsulation efficiency (EE) of 97.93 Â± 0.03%.",Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939551/),m,23.0,132049,DB00619,Imatinib
,25939551,drug loading (DL),"The optimized IMT-NLC exhibited a particle size (Sz) of 148.80 Â± 1.37 nm, polydispersity index (PDI) 0.191 Â± 0.017 of and Î¶-potential of -23.0 Â± 1.5 mV, with a drug loading (DL) of 5.48 Â± 0.01% and encapsulation efficiency (EE) of 97.93 Â± 0.03%.",Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939551/),%,5.48,132050,DB00619,Imatinib
,25939551,encapsulation efficiency (EE),"The optimized IMT-NLC exhibited a particle size (Sz) of 148.80 Â± 1.37 nm, polydispersity index (PDI) 0.191 Â± 0.017 of and Î¶-potential of -23.0 Â± 1.5 mV, with a drug loading (DL) of 5.48 Â± 0.01% and encapsulation efficiency (EE) of 97.93 Â± 0.03%.",Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939551/),%,97.93,132051,DB00619,Imatinib
,20644548,steady-state C(mins),"The overall mean (+/-SD, CV%) steady-state C(mins) for imatinib at 400 mg (n=36) and 600 mg (n=10) daily was 1325.61 ng/mL (+/-583.53 ng/mL; 44%) and 1550.90 ng/mL (+/-462.63 ng/mL; 30%), respectively, and no statistically significant differences were found between them (P=0.267).",Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20644548/),[ng] / [ml],1325.61,132572,DB00619,Imatinib
,20644548,steady-state C(mins),"The overall mean (+/-SD, CV%) steady-state C(mins) for imatinib at 400 mg (n=36) and 600 mg (n=10) daily was 1325.61 ng/mL (+/-583.53 ng/mL; 44%) and 1550.90 ng/mL (+/-462.63 ng/mL; 30%), respectively, and no statistically significant differences were found between them (P=0.267).",Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20644548/),[ng] / [ml],1550.90,132573,DB00619,Imatinib
,30514402,elimination half-lives,"In general, elimination half-lives of these agents in mice and guinea pigs were much shorter (1-3 h) relative to those in larger species such as prairie dogs and monkeys.",Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30514402/),h,1-3,134334,DB00619,Imatinib
,30514402,elimination half-life,"The longer nilotinib elimination half-life in prairie dogs (i.v., 6.5 h and oral, 7.5 h), facilitated multiple dosing PK and safety assessment.",Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30514402/),h,6.5,134335,DB00619,Imatinib
,30514402,elimination half-life,"The longer nilotinib elimination half-life in prairie dogs (i.v., 6.5 h and oral, 7.5 h), facilitated multiple dosing PK and safety assessment.",Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30514402/),h,7.5,134336,DB00619,Imatinib
,14747424,Absolute bioavailability,"Absolute bioavailability values (compared with i.v. infusion) for the imatinib capsule and oral solution were 98.3% and 97.2%, respectively.",Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747424/),%,98.3,134834,DB00619,Imatinib
,14747424,Absolute bioavailability,"Absolute bioavailability values (compared with i.v. infusion) for the imatinib capsule and oral solution were 98.3% and 97.2%, respectively.",Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747424/),%,97.2,134835,DB00619,Imatinib
>,14747424,bioavailable,"The 400-mg oral dose of imatinib, as a capsule or a solution, was completely absorbed and was almost completely bioavailable (> 97%).",Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747424/),%,97,134836,DB00619,Imatinib
,25389456,peak blood level,"The mean peak blood level of sunitinib in patients with fractioned doses was significantly lower than that in those with once-daily dose (83.4 vs 50.1 ng/ml, P = .01).",Fractioned dose regimen of sunitinib for patients with gastrointestinal stromal tumor: a pharmacokinetic and treatment efficacy study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25389456/),[ng] / [ml],83.4,139098,DB00619,Imatinib
,25389456,peak blood level,"The mean peak blood level of sunitinib in patients with fractioned doses was significantly lower than that in those with once-daily dose (83.4 vs 50.1 ng/ml, P = .01).",Fractioned dose regimen of sunitinib for patients with gastrointestinal stromal tumor: a pharmacokinetic and treatment efficacy study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25389456/),[ng] / [ml],50.1,139099,DB00619,Imatinib
,19695406,T(max),Median T(max) was ~2 hours after administration of single and multiple doses.,"Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),h,2,139225,DB00619,Imatinib
,19695406,C(min),"At steady state, C(min) was 1025.4 ng/mL and C(max) was 2160.7 ng/mL.","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),[ng] / [ml],1025.4,139226,DB00619,Imatinib
,19695406,C(max),"At steady state, C(min) was 1025.4 ng/mL and C(max) was 2160.7 ng/mL.","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),[ng] / [ml],2160.7,139227,DB00619,Imatinib
,19695406,AUCs from time 0 to the end of the dosing interval tau (AUC(0-tau)),"Mean AUCs from time 0 to the end of the dosing interval tau (AUC(0-tau)) were 5076.3 and 17,751.3 ng .","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),ng,5076.3,139228,DB00619,Imatinib
,19695406,AUCs from time 0 to the end of the dosing interval tau (AUC(0-tau)),"Mean AUCs from time 0 to the end of the dosing interval tau (AUC(0-tau)) were 5076.3 and 17,751.3 ng .","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),ng,"17,751.3",139229,DB00619,Imatinib
,19695406,accumulation factor,"h/mL at days 1 and 15, respectively, representing an accumulation factor of 3.92.","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),,3.92,139230,DB00619,Imatinib
,19695406,Apparent oral clearance (CL/F),"Apparent oral clearance (CL/F) was 0.39 L/h/kg (range, 0.12-0.74 L/h/ kg) at steady state.","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),[l] / [hÂ·kg],0.39,139231,DB00619,Imatinib
,22038662,AUC,"Sorafenib AUC significantly decreased over time: the median AUC during the third month of treatment was lower than that observed after one month of treatment (43.0 vs. 60.3 mg/L.h, p = 0.008).",Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22038662/),[mg] / [hÂ·l],43.0,143283,DB00619,Imatinib
,22038662,AUC,"Sorafenib AUC significantly decreased over time: the median AUC during the third month of treatment was lower than that observed after one month of treatment (43.0 vs. 60.3 mg/L.h, p = 0.008).",Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22038662/),[mg] / [hÂ·l],60.3,143284,DB00619,Imatinib
,22038662,AUC,"Most importantly, median sorafenib AUC at the time of progression was almost two-fold lower than that observed after one month of therapy (33.2 vs. 60.3 mg/L.h, p = 0.007).",Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22038662/),[mg] / [hÂ·l],33.2,143285,DB00619,Imatinib
,22038662,AUC,"Most importantly, median sorafenib AUC at the time of progression was almost two-fold lower than that observed after one month of therapy (33.2 vs. 60.3 mg/L.h, p = 0.007).",Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22038662/),[mg] / [hÂ·l],60.3,143286,DB00619,Imatinib
,30101387,progression free survival,Median progression free survival was 12.1 weeks (95% CI 4.7-19.5 weeks).,"A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30101387/),weeks,12.1,146575,DB00619,Imatinib
,24855354,IC50,Cytotoxicity assays demonstrated that the FR-targeted imatinib liposomes promoted a six-fold IC50 reduction on the non-targeted imatinib liposomes from 910 to 150 Î¼M.,Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24855354/),Î¼M,910,146990,DB00619,Imatinib
,24855354,IC50,Cytotoxicity assays demonstrated that the FR-targeted imatinib liposomes promoted a six-fold IC50 reduction on the non-targeted imatinib liposomes from 910 to 150 Î¼M.,Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24855354/),Î¼M,150,146991,DB00619,Imatinib
,24589908,CL/F,"Interestingly, 25 patients carrying at least one polymorphic c.480 G allele had a significant lower CL/F value with respect to the 35 c.480CC individuals (meanÂ±s.d., 9.6Â±1.6 vs 12.1Â±2.3 l h(-1), respectively; P<0.001).",The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24589908/),[l] / [h],9.6,148856,DB00619,Imatinib
,24589908,CL/F,"Interestingly, 25 patients carrying at least one polymorphic c.480 G allele had a significant lower CL/F value with respect to the 35 c.480CC individuals (meanÂ±s.d., 9.6Â±1.6 vs 12.1Â±2.3 l h(-1), respectively; P<0.001).",The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24589908/),[l] / [h],12.1,148857,DB00619,Imatinib
,31471313,progression-free survival,"Stable disease was the best response in 4 patients, and median progression-free survival was 1.9 months.",Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471313/),month,1.9,151029,DB00619,Imatinib
,26189007,zero-order kinetic (Fr),"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),,0.153,153324,DB00619,Imatinib
,26189007,Tk0),"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),h,0.714,153325,DB00619,Imatinib
,26189007,first-order absorption rate constant (k a),"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),1/[h],0.94,153326,DB00619,Imatinib
,26189007,oral clearance,"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),[l] / [h],19,153327,DB00619,Imatinib
,26189007,central volume of distribution (V c/F),"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),l,139,153328,DB00619,Imatinib
,26189007,apparent peripheral volume of distribution (V p/F),"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),l,130,153329,DB00619,Imatinib
,26189007,apparent inter-compartment clearance (Q/F),"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),[l] / [h],29.6,153330,DB00619,Imatinib
,28900995,Concentration,Concentration of IM (CIM) was (1 501.1Â±646.8) Î¼g/L and concentration of NDI (CNDI) was (221.7Â±92.5) Î¼g/L.,[Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28900995/),[Î¼g] / [l],1 501.1,155446,DB00619,Imatinib
,28900995,CIM,"The concentration of IM and NDI in patients with TC heterozygote was significantly lower than those with wildtype TT [CIM: (695.4Â±202.9) Î¼g/L vs. (1 518.9Â±716.8) Î¼g/L, P=0.002; CNDI:(133.3Â±59.8) Î¼g/L vs. (244.5Â±99.1) Î¼g/L, P=0.028].",[Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28900995/),[Î¼g] / [l],695.4,155447,DB00619,Imatinib
,28900995,CIM,"The concentration of IM and NDI in patients with TC heterozygote was significantly lower than those with wildtype TT [CIM: (695.4Â±202.9) Î¼g/L vs. (1 518.9Â±716.8) Î¼g/L, P=0.002; CNDI:(133.3Â±59.8) Î¼g/L vs. (244.5Â±99.1) Î¼g/L, P=0.028].",[Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28900995/),[Î¼g] / [l],1 518.9,155448,DB00619,Imatinib
,28900995,CNDI,"The concentration of IM and NDI in patients with TC heterozygote was significantly lower than those with wildtype TT [CIM: (695.4Â±202.9) Î¼g/L vs. (1 518.9Â±716.8) Î¼g/L, P=0.002; CNDI:(133.3Â±59.8) Î¼g/L vs. (244.5Â±99.1) Î¼g/L, P=0.028].",[Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28900995/),[Î¼g] / [l],133.3,155449,DB00619,Imatinib
,28900995,CNDI,"The concentration of IM and NDI in patients with TC heterozygote was significantly lower than those with wildtype TT [CIM: (695.4Â±202.9) Î¼g/L vs. (1 518.9Â±716.8) Î¼g/L, P=0.002; CNDI:(133.3Â±59.8) Î¼g/L vs. (244.5Â±99.1) Î¼g/L, P=0.028].",[Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28900995/),[Î¼g] / [l],244.5,155450,DB00619,Imatinib
,19650675,elimination half-life,"This approach was evaluated in silico and applied to imatinib and capecitabine, the pharmacokinetics of which are described in the literature, and which have quite different pharmacokinetic characteristics (imatinib has an elimination half-life of 17 hours, and alpha-fluoro-beta-alanine [FBAL], the metabolite of capecitabine, has an elimination half-life of 3 hours).",Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650675/),h,17,158525,DB00619,Imatinib
,19650675,elimination half-life,"This approach was evaluated in silico and applied to imatinib and capecitabine, the pharmacokinetics of which are described in the literature, and which have quite different pharmacokinetic characteristics (imatinib has an elimination half-life of 17 hours, and alpha-fluoro-beta-alanine [FBAL], the metabolite of capecitabine, has an elimination half-life of 3 hours).",Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650675/),h,3,158526,DB00619,Imatinib
,16006570,t(max),Absorption was rapid (t(max) 1-2 h) and complete with imatinib as the major radioactive compound in plasma.,Metabolism and disposition of imatinib mesylate in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),h,1-2,160062,DB00619,Imatinib
,16006570,Maximum plasma concentrations,"Maximum plasma concentrations were 0.921 +/- 0.095 mug/ml (mean +/- S.D., n = 4) for imatinib and 0.115 +/- 0.026 mug/ml for the pharmacologically active N-desmethyl metabolite (CGP74588).",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),[Î¼g] / [ml],0.921,160063,DB00619,Imatinib
,16006570,Maximum plasma concentrations,"Maximum plasma concentrations were 0.921 +/- 0.095 mug/ml (mean +/- S.D., n = 4) for imatinib and 0.115 +/- 0.026 mug/ml for the pharmacologically active N-desmethyl metabolite (CGP74588).",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),[Î¼g] / [ml],0.115,160064,DB00619,Imatinib
,16006570,plasma terminal elimination half-lives,"Mean plasma terminal elimination half-lives were 13.5 +/- 0.9 h for imatinib, 20.6 +/- 1.7 h for CGP74588, and 57.3 +/- 12.5 h for (14)C radioactivity.",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),h,13.5,160065,DB00619,Imatinib
,16006570,plasma terminal elimination half-lives,"Mean plasma terminal elimination half-lives were 13.5 +/- 0.9 h for imatinib, 20.6 +/- 1.7 h for CGP74588, and 57.3 +/- 12.5 h for (14)C radioactivity.",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),h,20.6,160066,DB00619,Imatinib
,16006570,plasma terminal elimination half-lives,"Mean plasma terminal elimination half-lives were 13.5 +/- 0.9 h for imatinib, 20.6 +/- 1.7 h for CGP74588, and 57.3 +/- 12.5 h for (14)C radioactivity.",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),h,57.3,160067,DB00619,Imatinib
,16006570,radiocarbon recovery,"Excretion of radioactivity was slow with a mean radiocarbon recovery of 80% within 7 days (67% in feces, 13% in urine).",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),%,80,160068,DB00619,Imatinib
,16006570,radiocarbon recovery,"Excretion of radioactivity was slow with a mean radiocarbon recovery of 80% within 7 days (67% in feces, 13% in urine).",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),%,67,160069,DB00619,Imatinib
,16006570,radiocarbon recovery,"Excretion of radioactivity was slow with a mean radiocarbon recovery of 80% within 7 days (67% in feces, 13% in urine).",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),%,13,160070,DB00619,Imatinib
,18256322,steady-state C(min),"The overall mean (+/- SD, CV%) steady-state C(min) for imatinib and CGP74588 were 979 ng/mL (+/- 530 ng/mL, 54.1%) and 242 ng/mL (+/- 106 ng/mL, 43.6%), respectively.",Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18256322/),[ng] / [ml],979,161733,DB00619,Imatinib
,18256322,steady-state C(min),"The overall mean (+/- SD, CV%) steady-state C(min) for imatinib and CGP74588 were 979 ng/mL (+/- 530 ng/mL, 54.1%) and 242 ng/mL (+/- 106 ng/mL, 43.6%), respectively.",Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18256322/),[ng] / [ml],242,161734,DB00619,Imatinib
,18256322,C(min),"C(min) of imatinib was significantly higher in patients who achieved CCyR (1009 +/- 544 ng/mL vs 812 +/- 409 ng/mL, P = .01).",Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18256322/),[ng] / [ml],1009,161735,DB00619,Imatinib
,18256322,C(min),"C(min) of imatinib was significantly higher in patients who achieved CCyR (1009 +/- 544 ng/mL vs 812 +/- 409 ng/mL, P = .01).",Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18256322/),[ng] / [ml],812,161736,DB00619,Imatinib
,33628019,zeta potential,"The IM-LPs showed an average size of 101.6 Â± 50.80 nm with a zeta potential value of 19.66 Â± 0.55 mV, a PDI of 0.250 and 81.96% Â± 0.98% drug entrapment efficiency, meanwhile displayed a sustained release profile.",In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628019/),mv,19.66,163863,DB00619,Imatinib
,33628019,PDI,"The IM-LPs showed an average size of 101.6 Â± 50.80 nm with a zeta potential value of 19.66 Â± 0.55 mV, a PDI of 0.250 and 81.96% Â± 0.98% drug entrapment efficiency, meanwhile displayed a sustained release profile.",In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628019/),,0.250,163864,DB00619,Imatinib
,22805325,prostatic serum antigen,The median age was 73 (57-89); median prostatic serum antigen was 284 ng ml(-1) (11.7-9027).,Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22805325/),[ng] / [ml],284,167818,DB00619,Imatinib
,22805325,time to progression,Median time to progression was 2 months (1-5).,Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22805325/),month,2,167819,DB00619,Imatinib
,19248046,MTD,The MTD of vatalanib for all patients was 1000 mg twice-a-day.,Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19248046/),mg,1000,168805,DB00619,Imatinib
,20980997,IM-C(min),"Among 254 CML patients, the mean IM-C(min) was 1,010.5 ng/ml.",Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20980997/),[ng] / [ml],"1,010.5",169050,DB00619,Imatinib
>,20980997,C(min),"Given that patients with IM-C(min) values >1,002 ng/ml had a higher probability of achieving an MMR in our large cohort (P = 0.0120), the data suggest that monitoring of IM levels in plasma may improve the efficacy of IM therapy for CML patients.",Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20980997/),[ng] / [ml],"1,002",169051,DB00619,Imatinib
,31951849,Ka,"Thus, association constant was determined as Ka = 873.36 M-1.",Study of the binding affinity between imatinib and Î±-1 glycoprotein using nuclear spin relaxation and isothermal titration calorimetry. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31951849/),1/[M],873.36,175364,DB00619,Imatinib
,31951849,association constant Ka,"The ITC data revealed that the binding was an entropy driven process and the association constant Ka = 3.22 Ã 103 M-1, with a 1:1 stoichiometry.",Study of the binding affinity between imatinib and Î±-1 glycoprotein using nuclear spin relaxation and isothermal titration calorimetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31951849/),1/[M],3.22 Ã 103,175365,DB00619,Imatinib
,30767712,Ka (1/,The final PPK model is: Ka (1/h) = 0.329; CL/F (l/h) = 9.25 Ã (actual bodyweight/70)0.228; V/F(l) = 222.,Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia. ,"t1/2,Î±-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30767712/),,0,176251,DB00619,Imatinib
,30767712,V/F,The final PPK model is: Ka (1/h) = 0.329; CL/F (l/h) = 9.25 Ã (actual bodyweight/70)0.228; V/F(l) = 222.,Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30767712/),l,222,176252,DB00619,Imatinib
,16914578,maximum tolerated dose,The maximum tolerated dose for non-EIAED patients was 800 mg/d.,Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16914578/),mg,800,185829,DB00619,Imatinib
,16914578,progression-free survival,Six-month progression-free survival was 3% for glioblastoma multiforme and 10% for anaplastic glioma patients.,Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16914578/),%,3,185830,DB00619,Imatinib
,16914578,progression-free survival,Six-month progression-free survival was 3% for glioblastoma multiforme and 10% for anaplastic glioma patients.,Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16914578/),%,10,185831,DB00619,Imatinib
,20957481,progression-free survival (PFS),"Median progression-free survival (PFS) and overall survival (OS) were 23.6 weeks (95% confidence interval [CI] 0.0-50.6 weeks) and 74.0 weeks (95% CI 27.4-120.6 weeks), respectively.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),weeks,23.6,186383,DB00619,Imatinib
,20957481,overall survival (OS),"Median progression-free survival (PFS) and overall survival (OS) were 23.6 weeks (95% confidence interval [CI] 0.0-50.6 weeks) and 74.0 weeks (95% CI 27.4-120.6 weeks), respectively.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),weeks,74.0,186384,DB00619,Imatinib
,20957481,C (max),"Pharmacokinetic parameters of nilotinib were as follows: C (max) of 1,754 Â± 970 Î¼g/L, T(1/2) of 13.4 Â± 8.94 h and AUC (0-12 h) of 14,190 Â± 6,853 h Î¼g/L.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[Î¼g] / [l],"1,754",186385,DB00619,Imatinib
,20957481,T(1/2),"Pharmacokinetic parameters of nilotinib were as follows: C (max) of 1,754 Â± 970 Î¼g/L, T(1/2) of 13.4 Â± 8.94 h and AUC (0-12 h) of 14,190 Â± 6,853 h Î¼g/L.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),h,13.4,186386,DB00619,Imatinib
,20957481,AUC (0-12 h),"Pharmacokinetic parameters of nilotinib were as follows: C (max) of 1,754 Â± 970 Î¼g/L, T(1/2) of 13.4 Â± 8.94 h and AUC (0-12 h) of 14,190 Â± 6,853 h Î¼g/L.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[hÂ·Î¼g] / [l],"14,190",186387,DB00619,Imatinib
,20957481,AUC (0-12 h),"The AUC (0-12 h) of nilotinib was significantly lower in the 4 patients with prior major (total or subtotal) gastrectomy than in the other 13 patients (8,526 Â± 7,869 h Î¼g/L vs. 15,930 Â± 5,759 h Î¼g/L, P = 0.014).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[hÂ·Î¼g] / [l],"8,526",186388,DB00619,Imatinib
,20957481,AUC (0-12 h),"The AUC (0-12 h) of nilotinib was significantly lower in the 4 patients with prior major (total or subtotal) gastrectomy than in the other 13 patients (8,526 Â± 7,869 h Î¼g/L vs. 15,930 Â± 5,759 h Î¼g/L, P = 0.014).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[hÂ·Î¼g] / [l],"15,930",186389,DB00619,Imatinib
,20957481,AUC (0-12 h),"Of the 4 gastrectomized patients, two (50%) showed markedly decreased nilotinib exposure (AUC (0-12 h) of 1,914 and 3,194 h Î¼g/L) and rapid disease progression (PFS of 4.6 and 7.1 weeks).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[hÂ·Î¼g] / [l],"1,914",186390,DB00619,Imatinib
,20957481,AUC (0-12 h),"Of the 4 gastrectomized patients, two (50%) showed markedly decreased nilotinib exposure (AUC (0-12 h) of 1,914 and 3,194 h Î¼g/L) and rapid disease progression (PFS of 4.6 and 7.1 weeks).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[hÂ·Î¼g] / [l],"3,194",186391,DB00619,Imatinib
,25102852,"AUC24,ss","The geometric mean of sunitinib and SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n = 8) compared to controls (n = 63) for sunitinib (931 ng hr/mL (95%-CI; 676-1283) versus 1177 ng hr/mL (95%-CI; 1097-1263); p < 0.05) and SU12662 (354 ng hr/mL (95%-CI; 174-720) versus 492 ng hr/mL (95%-CI; 435-555); p < 0.05).",Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102852/),[hÂ·ng] / [ml],931,188378,DB00619,Imatinib
,25102852,"AUC24,ss","The geometric mean of sunitinib and SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n = 8) compared to controls (n = 63) for sunitinib (931 ng hr/mL (95%-CI; 676-1283) versus 1177 ng hr/mL (95%-CI; 1097-1263); p < 0.05) and SU12662 (354 ng hr/mL (95%-CI; 174-720) versus 492 ng hr/mL (95%-CI; 435-555); p < 0.05).",Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102852/),[hÂ·ng] / [ml],1177,188379,DB00619,Imatinib
,25102852,"AUC24,ss","The geometric mean of sunitinib and SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n = 8) compared to controls (n = 63) for sunitinib (931 ng hr/mL (95%-CI; 676-1283) versus 1177 ng hr/mL (95%-CI; 1097-1263); p < 0.05) and SU12662 (354 ng hr/mL (95%-CI; 174-720) versus 492 ng hr/mL (95%-CI; 435-555); p < 0.05).",Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102852/),[hÂ·ng] / [ml],354,188380,DB00619,Imatinib
,25102852,"AUC24,ss","The geometric mean of sunitinib and SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n = 8) compared to controls (n = 63) for sunitinib (931 ng hr/mL (95%-CI; 676-1283) versus 1177 ng hr/mL (95%-CI; 1097-1263); p < 0.05) and SU12662 (354 ng hr/mL (95%-CI; 174-720) versus 492 ng hr/mL (95%-CI; 435-555); p < 0.05).",Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102852/),[hÂ·ng] / [ml],492,188381,DB00619,Imatinib
,32415468,AUC0-72,"Volunteers (n = 26; aged 24 Â± 3 years; 69% male) presented regular pharmacokinetic imatinib data (concentration at 24 h, 436 Â± 140 ng/mL and at 72 h, 40 Â± 26 ng/mL; AUC0-72 32,868 Â± 10,713 ng/mLâh; and Cmax 2074 Â± 604 ng/mL).",Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415468/),[ng] / [hÂ·ml],"32,868",188967,DB00619,Imatinib
,32415468,Cmax,"Volunteers (n = 26; aged 24 Â± 3 years; 69% male) presented regular pharmacokinetic imatinib data (concentration at 24 h, 436 Â± 140 ng/mL and at 72 h, 40 Â± 26 ng/mL; AUC0-72 32,868 Â± 10,713 ng/mLâh; and Cmax 2074 Â± 604 ng/mL).",Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415468/),[ng] / [ml],2074,188968,DB00619,Imatinib
,32415468,elimination half-life,"CYP2B6 516GT carriers showed a significant reduction of imatinib concentration at 24 h (23%, 391 ng/dL vs 511 ng/dL in 516GG carriers, p = 0.005) and elimination half-life (11%, 12.6 h vs 14.1 h in 516GG carriers, p = 0.041).",Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415468/),%,11,188969,DB00619,Imatinib
,32415468,elimination half-life,"CYP2B6 516GT carriers showed a significant reduction of imatinib concentration at 24 h (23%, 391 ng/dL vs 511 ng/dL in 516GG carriers, p = 0.005) and elimination half-life (11%, 12.6 h vs 14.1 h in 516GG carriers, p = 0.041).",Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415468/),h,12.6,188970,DB00619,Imatinib
,32415468,elimination half-life,"CYP2B6 516GT carriers showed a significant reduction of imatinib concentration at 24 h (23%, 391 ng/dL vs 511 ng/dL in 516GG carriers, p = 0.005) and elimination half-life (11%, 12.6 h vs 14.1 h in 516GG carriers, p = 0.041).",Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415468/),h,14.1,188971,DB00619,Imatinib
,24549963,Cmax,"The Cmax value was 922.8Â±318.8 Î¼g/L at 3.15 h for 200-mg imatinib tablet, and 986.3Â±266.0 Î¼g/L at 2.91 h for the 2Ã100-mg imatinib tablet.",Bioequivalence study of two imatinib formulations after single-dose administration in healthy Korean male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24549963/),[Î¼g] / [l],922.8,194378,DB00619,Imatinib
,24549963,Cmax,"The Cmax value was 922.8Â±318.8 Î¼g/L at 3.15 h for 200-mg imatinib tablet, and 986.3Â±266.0 Î¼g/L at 2.91 h for the 2Ã100-mg imatinib tablet.",Bioequivalence study of two imatinib formulations after single-dose administration in healthy Korean male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24549963/),[Î¼g] / [l],986.3,194379,DB00619,Imatinib
,24549963,AUClast,"The AUClast of 200-mg and 2Ã100-mg tablets were 13 084.3Â±39.1 and 14 131.7Â±3 826.2 h Â· Î¼g/L, respectively.",Bioequivalence study of two imatinib formulations after single-dose administration in healthy Korean male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24549963/),[hÂ·Î¼g] / [l],13 084.3,194380,DB00619,Imatinib
,24549963,AUClast,"The AUClast of 200-mg and 2Ã100-mg tablets were 13 084.3Â±39.1 and 14 131.7Â±3 826.2 h Â· Î¼g/L, respectively.",Bioequivalence study of two imatinib formulations after single-dose administration in healthy Korean male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24549963/),[hÂ·Î¼g] / [l],14 131.7,194381,DB00619,Imatinib
,34230967,m/z,An efficient chromatographic separation was performed and detection was achieved by monitoring precursor-to-product ion transitions with m/z 557.29 â 112.06 for neratinib and m/z 494.43 â 294.17 for IS.,Development of a Validated Bioanalytical UPLC-MS/MS Method for Quantification of Neratinib: A Recent Application to Pharmacokinetic Studies in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34230967/),,557.29,195759,DB00619,Imatinib
,34230967,m/z,An efficient chromatographic separation was performed and detection was achieved by monitoring precursor-to-product ion transitions with m/z 557.29 â 112.06 for neratinib and m/z 494.43 â 294.17 for IS.,Development of a Validated Bioanalytical UPLC-MS/MS Method for Quantification of Neratinib: A Recent Application to Pharmacokinetic Studies in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34230967/),,112.06,195760,DB00619,Imatinib
,34230967,m/z,An efficient chromatographic separation was performed and detection was achieved by monitoring precursor-to-product ion transitions with m/z 557.29 â 112.06 for neratinib and m/z 494.43 â 294.17 for IS.,Development of a Validated Bioanalytical UPLC-MS/MS Method for Quantification of Neratinib: A Recent Application to Pharmacokinetic Studies in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34230967/),,494.43,195761,DB00619,Imatinib
,34230967,m/z,An efficient chromatographic separation was performed and detection was achieved by monitoring precursor-to-product ion transitions with m/z 557.29 â 112.06 for neratinib and m/z 494.43 â 294.17 for IS.,Development of a Validated Bioanalytical UPLC-MS/MS Method for Quantification of Neratinib: A Recent Application to Pharmacokinetic Studies in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34230967/),,294.17,195762,DB00619,Imatinib
,34230967,extraction recovery,"Mean extraction recovery for neratinib and IS were 99.44 and 99.33%, while matrix effect for neratinib and IS was ranging between -4.35 and - 3.66%, respectively.",Development of a Validated Bioanalytical UPLC-MS/MS Method for Quantification of Neratinib: A Recent Application to Pharmacokinetic Studies in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34230967/),%,99.44,195763,DB00619,Imatinib
,34230967,extraction recovery,"Mean extraction recovery for neratinib and IS were 99.44 and 99.33%, while matrix effect for neratinib and IS was ranging between -4.35 and - 3.66%, respectively.",Development of a Validated Bioanalytical UPLC-MS/MS Method for Quantification of Neratinib: A Recent Application to Pharmacokinetic Studies in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34230967/),%,99.33,195764,DB00619,Imatinib
,19258444,CL/F,"Sunitinib parameters were estimated as CL/F, 51.8 L/h and Vd/F(central), 2,030 liters.",A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258444/),[l] / [h],51.8,199094,DB00619,Imatinib
,19258444,Vd/F(central),"Sunitinib parameters were estimated as CL/F, 51.8 L/h and Vd/F(central), 2,030 liters.",A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258444/),l,"2,030",199095,DB00619,Imatinib
,19258444,CL/F,"SU12662 parameters were estimated as CL/F, 29.6 L/h and Vd/F(central), 3,080 liters.",A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258444/),[l] / [h],29.6,199096,DB00619,Imatinib
,19258444,Vd/F(central),"SU12662 parameters were estimated as CL/F, 29.6 L/h and Vd/F(central), 3,080 liters.",A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258444/),l,"3,080",199097,DB00619,Imatinib
,18553235,progression-free survival time,The median progression-free survival time was 96 weeks.,Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18553235/),weeks,96,200082,DB00619,Imatinib
,33214787,At steady state,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ngÂ·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ngÂ·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],89.2,200125,DB00619,Imatinib
,33214787,At steady state,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ngÂ·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ngÂ·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],141.1,200126,DB00619,Imatinib
,33214787,At steady state,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ngÂ·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ngÂ·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],18.9,200127,DB00619,Imatinib
,33214787,maximum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ngÂ·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ngÂ·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],18.9,200128,DB00619,Imatinib
,33214787,minimum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ngÂ·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ngÂ·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],16.7,200129,DB00619,Imatinib
,33214787,minimum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ngÂ·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ngÂ·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],141.1,200130,DB00619,Imatinib
,33214787,minimum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ngÂ·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ngÂ·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[ng] / [ml],18.9,200131,DB00619,Imatinib
,33214787,minimum plasma concentration,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ngÂ·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ngÂ·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[hÂ·ng] / [ml],1278.5,200132,DB00619,Imatinib
,33214787,area under the plasma concentration-time curve,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ngÂ·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ngÂ·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[hÂ·ng] / [ml],1017.4,200133,DB00619,Imatinib
,33214787,area under the plasma concentration-time curve,"At steady state, maximum plasma concentration, minimum plasma concentration, and area under the plasma concentration-time curve were 89.2 ng/mL, 16.7 ng/mL, and 1017.4 ngÂ·hr/mL, respectively, at 290 mg/m2/day; and 141.1 ng/mL, 18.9 ng/mL, and 1278.5 ngÂ·hr/mL, respectively, at 330 mg/m2/day.","Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214787/),[hÂ·ng] / [ml],1278.5,200134,DB00619,Imatinib
,33356314,zeta potential,"Results displayed that IMS-LF-LCNPs presented an optimum particle size of 120.40 Â± 2.75 nm, a zeta potential of +12.5 Â± 0.23 mV, and 73.94 Â± 2.69% release.",Fabrication of Imatinib Mesylate-Loaded Lactoferrin-Modified PEGylated Liquid Crystalline Nanoparticles for Mitochondrial-Dependent Apoptosis in Hepatocellular Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33356314/),m,12.5,201257,DB00619,Imatinib
,23301703,K(d),"It tightly bound to Bcr-Abl(WT) and Bcr-Abl(T315I) with K(d) values of 0.32 and 0.71 nM, respectively, and strongly inhibited the kinase functions with nanomolar IC(50) values.",Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301703/),nM,0.32,202317,DB00619,Imatinib
,23301703,K(d),"It tightly bound to Bcr-Abl(WT) and Bcr-Abl(T315I) with K(d) values of 0.32 and 0.71 nM, respectively, and strongly inhibited the kinase functions with nanomolar IC(50) values.",Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301703/),nM,0.71,202318,DB00619,Imatinib
,23301703,IC(50),"The compound potently suppressed proliferation of Bcr-Abl-positive K562 and Ku812 human CML cells with IC(50) values of 0.2 and 0.13 nM, respectively.",Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301703/),nM,0.2,202319,DB00619,Imatinib
,23301703,IC(50),"The compound potently suppressed proliferation of Bcr-Abl-positive K562 and Ku812 human CML cells with IC(50) values of 0.2 and 0.13 nM, respectively.",Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301703/),nM,0.13,202320,DB00619,Imatinib
,23301703,oral bioavailability,"It also displayed good oral bioavailability (48.7%), a reasonable half-life (10.6 h), and promising in vivo antitumor efficacy.",Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301703/),%,48.7,202321,DB00619,Imatinib
,23301703,half-life,"It also displayed good oral bioavailability (48.7%), a reasonable half-life (10.6 h), and promising in vivo antitumor efficacy.",Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301703/),h,10.6,202322,DB00619,Imatinib
,28191803,clearance,"A one-compartment model with first-order absorption appropriately described the data, giving a mean (Â±SEM) clearance of 14.3l (Â±1.0) and a volume of distribution of 347 l (Â±62).",Population Pharmacokinetics of Imatinib and its application to the therapeutic drug monitoring: Middle East CML population. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28191803/),l,14.3,203064,DB00619,Imatinib
,28191803,volume of distribution,"A one-compartment model with first-order absorption appropriately described the data, giving a mean (Â±SEM) clearance of 14.3l (Â±1.0) and a volume of distribution of 347 l (Â±62).",Population Pharmacokinetics of Imatinib and its application to the therapeutic drug monitoring: Middle East CML population. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28191803/),l,347,203065,DB00619,Imatinib
,17634544,area under plasma concentration time curve,"Comparison of plasma concentrations determined by AMS with those derived by LCMS analysis gave similar average estimates of area under plasma concentration time curve (26 +/- 3 versus 27 +/- 11 microg/mL.h), but with some variation within each individual.",Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634544/),[Î¼g] / [hÂ·ml],26,203622,DB00619,Imatinib
,17634544,area under plasma concentration time curve,"Comparison of plasma concentrations determined by AMS with those derived by LCMS analysis gave similar average estimates of area under plasma concentration time curve (26 +/- 3 versus 27 +/- 11 microg/mL.h), but with some variation within each individual.",Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634544/),[Î¼g] / [hÂ·ml],27,203623,DB00619,Imatinib
,23591629,progression-free survival (PFS),The median progression-free survival (PFS) was 5.1 months.,"Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23591629/),month,5.1,205761,DB00619,Imatinib
,23591629,PFS,"There was a strong tendency for better PFS in patients with KIT exon 9 mutations compared to patients with other genotypes (median PFS 11 vs 4 months, p=0.051).","Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23591629/),month,11,205762,DB00619,Imatinib
,23591629,PFS,"There was a strong tendency for better PFS in patients with KIT exon 9 mutations compared to patients with other genotypes (median PFS 11 vs 4 months, p=0.051).","Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23591629/),month,4,205763,DB00619,Imatinib
,23591629,Cmin,"Mean Â± standard deviation imatinib Cmin at 800 mg/day and percent Cmin change was 3,552 Â± 1,540 ng/mL and 160 Â± 101 %, respectively.","Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23591629/),[ng] / [ml],"3,552",205764,DB00619,Imatinib
,23591629,percent Cmin change,"Mean Â± standard deviation imatinib Cmin at 800 mg/day and percent Cmin change was 3,552 Â± 1,540 ng/mL and 160 Â± 101 %, respectively.","Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23591629/),[ng] / [ml],"3,552",205765,DB00619,Imatinib
,23591629,percent Cmin change,"Mean Â± standard deviation imatinib Cmin at 800 mg/day and percent Cmin change was 3,552 Â± 1,540 ng/mL and 160 Â± 101 %, respectively.","Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23591629/),%,160,205766,DB00619,Imatinib
,20931790,AUC(0-->infinity),"The AUC(0-->infinity) was 11.24 microg x h x mL(-1), the elimination rate constant (k(el)) was 0.348 h(-1) and the elimination half life (t(1/2)) was 2.0 h.",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[hÂ·Î¼g] / [ml],11.24,206020,DB00619,Imatinib
,20931790,elimination rate constant (k(el)),"The AUC(0-->infinity) was 11.24 microg x h x mL(-1), the elimination rate constant (k(el)) was 0.348 h(-1) and the elimination half life (t(1/2)) was 2.0 h.",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),1/[h],0.348,206021,DB00619,Imatinib
,20931790,elimination half life (t(1/2)),"The AUC(0-->infinity) was 11.24 microg x h x mL(-1), the elimination rate constant (k(el)) was 0.348 h(-1) and the elimination half life (t(1/2)) was 2.0 h.",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),h,2.0,206022,DB00619,Imatinib
,20931790,mean residence time (MRT),"The mean residence time (MRT) was 2.59 h, V(SS) was 1.44 L x kg(-1) and clearance was 0.56 L x h x kg(-1).",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),h,2.59,206023,DB00619,Imatinib
,20931790,V(SS),"The mean residence time (MRT) was 2.59 h, V(SS) was 1.44 L x kg(-1) and clearance was 0.56 L x h x kg(-1).",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[l] / [kg],1.44,206024,DB00619,Imatinib
,20931790,clearance,"The mean residence time (MRT) was 2.59 h, V(SS) was 1.44 L x kg(-1) and clearance was 0.56 L x h x kg(-1).",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[hÂ·l] / [kg],0.56,206025,DB00619,Imatinib
,20931790,CMAX,Liver achieved the highest tissue exposure: CMAX = 18.72 microg x mL(-1); AUC(0-->infinity)= 58.18 microg x h x mL(-1) and longest t(1/2) (4.29 h) and MRT (5.31 h).,Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[Î¼g] / [ml],18.72,206026,DB00619,Imatinib
,20931790,AUC(0-->infinity),Liver achieved the highest tissue exposure: CMAX = 18.72 microg x mL(-1); AUC(0-->infinity)= 58.18 microg x h x mL(-1) and longest t(1/2) (4.29 h) and MRT (5.31 h).,Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[hÂ·Î¼g] / [ml],58.18,206027,DB00619,Imatinib
,20931790,t(1/2),Liver achieved the highest tissue exposure: CMAX = 18.72 microg x mL(-1); AUC(0-->infinity)= 58.18 microg x h x mL(-1) and longest t(1/2) (4.29 h) and MRT (5.31 h).,Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),h,4.29,206028,DB00619,Imatinib
,20931790,MRT,Liver achieved the highest tissue exposure: CMAX = 18.72 microg x mL(-1); AUC(0-->infinity)= 58.18 microg x h x mL(-1) and longest t(1/2) (4.29 h) and MRT (5.31 h).,Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),h,5.31,206029,DB00619,Imatinib
,20931790,AUC(0-->infinity),"Kidney and spleen AUC(0-->infinity) were 47.98 microg x h x mL(-1) and 23.46 microg x h x mL(-1), respectively.",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[hÂ·Î¼g] / [ml],47.98,206030,DB00619,Imatinib
,20931790,AUC(0-->infinity),"Kidney and spleen AUC(0-->infinity) were 47.98 microg x h x mL(-1) and 23.46 microg x h x mL(-1), respectively.",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[hÂ·Î¼g] / [ml],23.46,206031,DB00619,Imatinib
,20931790,Half-life,Half-life was 1.83 h for the kidney and 3.37 h for the spleen.,Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),h,1.83,206032,DB00619,Imatinib
,20931790,Half-life,Half-life was 1.83 h for the kidney and 3.37 h for the spleen.,Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),h,3.37,206033,DB00619,Imatinib
,27473308,zeta potential,Particles size was below 100nm in diameter and zeta potential ranged - (25-30).,Modified-chitosan nanoparticles: Novel drug delivery systems improve oral bioavailability of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473308/),,25-30,206887,DB00619,Imatinib
,15592836,apparent CL,"For a patient with 77% of the median body weight or with 1.87 times the median granulocyte count, the apparent CL is 6.53 l/h, about 70% of the typical apparent CL of 9.33 l/h; for a patient of 84% of the typical haemoglobin level, the volume of distribution is about 70%.",Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592836/),[l] / [h],6.53,207031,DB00619,Imatinib
,15592836,apparent CL,"For a patient with 77% of the median body weight or with 1.87 times the median granulocyte count, the apparent CL is 6.53 l/h, about 70% of the typical apparent CL of 9.33 l/h; for a patient of 84% of the typical haemoglobin level, the volume of distribution is about 70%.",Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592836/),[l] / [h],9.33,207032,DB00619,Imatinib
,28618035,apparent steady-state clearance,"The mean population-derived apparent steady-state clearance, elimination half-life, area under the concentration-time curve over 24 hours, and volume of distribution were 17.2 Â± 1.8 L/h., 12.05 Â± 2.1 hours, 23.26 Â± 0.6 Î¼gÂ·h/mL, and 299 Â± 20.4 L, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),[l] / [h],17.2,207500,DB00619,Imatinib
,28618035,elimination half-life,"The mean population-derived apparent steady-state clearance, elimination half-life, area under the concentration-time curve over 24 hours, and volume of distribution were 17.2 Â± 1.8 L/h., 12.05 Â± 2.1 hours, 23.26 Â± 0.6 Î¼gÂ·h/mL, and 299 Â± 20.4 L, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),h,12.05,207501,DB00619,Imatinib
,28618035,elimination half-life,"The mean population-derived apparent steady-state clearance, elimination half-life, area under the concentration-time curve over 24 hours, and volume of distribution were 17.2 Â± 1.8 L/h., 12.05 Â± 2.1 hours, 23.26 Â± 0.6 Î¼gÂ·h/mL, and 299 Â± 20.4 L, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),[hÂ·Î¼g] / [ml],23.26,207502,DB00619,Imatinib
,28618035,area under the concentration-time curve over 24 hours,"The mean population-derived apparent steady-state clearance, elimination half-life, area under the concentration-time curve over 24 hours, and volume of distribution were 17.2 Â± 1.8 L/h., 12.05 Â± 2.1 hours, 23.26 Â± 0.6 Î¼gÂ·h/mL, and 299 Â± 20.4 L, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),h,12.05,207503,DB00619,Imatinib
,28618035,volume of distribution,"The mean population-derived apparent steady-state clearance, elimination half-life, area under the concentration-time curve over 24 hours, and volume of distribution were 17.2 Â± 1.8 L/h., 12.05 Â± 2.1 hours, 23.26 Â± 0.6 Î¼gÂ·h/mL, and 299 Â± 20.4 L, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),l,299,207504,DB00619,Imatinib
,28618035,clearance,"Whole blood count, ethnicity, CYP3A5*3, and ABCB1 C3435T were found to have significant influence on the apparent clearance, while the interindividual variability in clearance and interoccasion variability in bioavailability were 17.4% and 20.4%, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),%,17.4,207505,DB00619,Imatinib
,28618035,bioavailability,"Whole blood count, ethnicity, CYP3A5*3, and ABCB1 C3435T were found to have significant influence on the apparent clearance, while the interindividual variability in clearance and interoccasion variability in bioavailability were 17.4% and 20.4%, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),%,20.4,207506,DB00619,Imatinib
,17523053,time of the peak concentration (T(max)),Imatinib was administered orally or intravenously to dogs and the time of the peak concentration (T(max)) of imatinib was 4-9 h.,Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),h,4-9,207990,DB00619,Imatinib
,17523053,half-life,"The mean half-life was 622 +/- 368 min, and the AUC was 1256 +/- 809 microM * min after oral administration.",Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),min,622,207991,DB00619,Imatinib
,17523053,AUC,"The mean half-life was 622 +/- 368 min, and the AUC was 1256 +/- 809 microM * min after oral administration.",Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),minÂ·Î¼M,1256,207992,DB00619,Imatinib
,17523053,C0,The range of C0 of intravenously injected dogs was 12-24 microM.,Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),Î¼M,12-24,207993,DB00619,Imatinib
,17523053,half-life,"The half-life and AUC after intravenous injection were 206 +/- 112 min and 1026 +/- 371 microM * min, respectively.",Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),min,206,207994,DB00619,Imatinib
,17523053,AUC,"The half-life and AUC after intravenous injection were 206 +/- 112 min and 1026 +/- 371 microM * min, respectively.",Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),minÂ·Î¼M,1026,207995,DB00619,Imatinib
<,27435281,C min,"The analyses included the occurrence of a low imatinib C min (<1000 Âµg/L), the change in the C min over time and the correlation between exposure and response.",Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27435281/),[Î¼g] / [l],1000,211848,DB00619,Imatinib
<,27435281,C min,"In the first steady-state sample, 44.4 % of patients presented with C min values <1000 Âµg/L; 32.4 % of patients had values <1000 Âµg/L in >75 % of their samples.",Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27435281/),[Î¼g] / [l],1000,211849,DB00619,Imatinib
â¥,27435281,C min,Only 33.3 % of patients had C min values â¥1000 Âµg/L in all measured samples.,Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27435281/),[Î¼g] / [l],1000,211850,DB00619,Imatinib
,27435281,C min,Fifty-seven (91.9 %) of 62 palliative-treated patients had a tumour response (median C min 1271 Âµg/L).,Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27435281/),[Î¼g] / [l],1271,211851,DB00619,Imatinib
,27435281,C min,Five palliative patients (8.1 %) did not respond (median C min 920 Âµg/L).,Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27435281/),[Î¼g] / [l],920,211852,DB00619,Imatinib
,14990650,plasma trough concentration,"Mean plasma trough concentration was 0.57 microg/mL (approximately 1 micromol/L) 24 hours after administration of 350 mg of imatinib at steady-state, which exceeds the 50% inhibitory concentration required to inhibit proliferation of Bcr-Abl-positive leukemic cells.",Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14990650/),[Î¼g] / [ml],0.57,211888,DB00619,Imatinib
,21234641,C(min),"Mean inter- and intra-subject variability values were 47.7% and 20.9%, respectively, at initial measurements, and 45.2% and 19.4%, respectively, at FU. Mean FU imatinib C(min) (1,370 Â± 661 ng/mL) was significantly higher than mean initial C(min) (1,171 Â± 573 ng/mL; p = 0.003).",Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21234641/),[ng] / [ml],"1,370",212128,DB00619,Imatinib
,21234641,C(min),"Mean inter- and intra-subject variability values were 47.7% and 20.9%, respectively, at initial measurements, and 45.2% and 19.4%, respectively, at FU. Mean FU imatinib C(min) (1,370 Â± 661 ng/mL) was significantly higher than mean initial C(min) (1,171 Â± 573 ng/mL; p = 0.003).",Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21234641/),[ng] / [ml],"1,171",212129,DB00619,Imatinib
,18384443,K(i),"Imatinib, a tyrosine kinase inhibitor, exhibits a competitive inhibition on the CYP450 2D6 isozyme with a K(i) value of 7.5 microm.","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),Î¼m,7.5,212302,DB00619,Imatinib
,18384443,AUC,"In the presence of 400 mg twice daily imatinib, the mean metoprolol AUC was increased by 17% in IMs (from 1190 to 1390 ng ml(-1) h), and 24% in EMs (from 660 to 818 ng ml(-1) h).","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),[hÂ·ng] / [ml],1190 to 1390,212303,DB00619,Imatinib
,18384443,AUC,"In the presence of 400 mg twice daily imatinib, the mean metoprolol AUC was increased by 17% in IMs (from 1190 to 1390 ng ml(-1) h), and 24% in EMs (from 660 to 818 ng ml(-1) h).","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),[hÂ·ng] / [ml],660 to 818,212304,DB00619,Imatinib
,18384443,oral clearance,"The oral clearance of imatinib was 11.0 +/- 2.0 l h(-1) and 11.8 +/- 4.1 l h(-1) for CYP2D6 IMs and EMs, respectively.","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),[l] / [h],11.0,212305,DB00619,Imatinib
,18384443,oral clearance,"The oral clearance of imatinib was 11.0 +/- 2.0 l h(-1) and 11.8 +/- 4.1 l h(-1) for CYP2D6 IMs and EMs, respectively.","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),[l] / [h],11.8,212306,DB00619,Imatinib
,32697563,trough imatinib concentration,"Achieving a major molecular response early in treatment, as indicated by a BCR-ABL1 major international scale result of â¤0.1% within 6 months, is associated with better patient outcomes and is statistically associated with a trough imatinib concentration of approximately 1000 ng/mL.",Evaluation of Imatinib Concentrations in Samples Submitted for BCR-ABL1 or Imatinib Testing-Evidence to Support Therapeutic Drug Monitoring for Dose Optimization? ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32697563/),[ng] / [ml],1000,213755,DB00619,Imatinib
,16890580,apparent oral clearance,"The apparent oral clearance of imatinib was potentially reduced in individuals with at least 1 CYP2D6*4 allele (median, 7.78 versus 10.6 L/h; P = .0695).",Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890580/),[l] / [h],7.78,214333,DB00619,Imatinib
,16890580,apparent oral clearance,"The apparent oral clearance of imatinib was potentially reduced in individuals with at least 1 CYP2D6*4 allele (median, 7.78 versus 10.6 L/h; P = .0695).",Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890580/),[l] / [h],10.6,214334,DB00619,Imatinib
,24292055,trough plasma levels,Therapeutic drug monitoring targeting trough plasma levels of about 1000 ng/mL may help to optimize imantinib's therapeutic effect.,Development of a specific and sensitive enzyme-linked immunosorbent assay for the quantification of imatinib. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24292055/),[ng] / [ml],1000,220453,DB00619,Imatinib
,31676669,area under the concentration-time curve at steady state,"The area under the concentration-time curve at steady state was slightly lower in pediatric patients versus adults (14,751.4 vs. 17,102.9 ng/h/mL); the geometric mean ratio (GMR; pediatric:adult) was 0.86 [90% confidence interval (CI), 0.70-1.06].",Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31676669/),[ng] / [hÂ·ml],"14,751.4",221031,DB00619,Imatinib
,31676669,area under the concentration-time curve at steady state,"The area under the concentration-time curve at steady state was slightly lower in pediatric patients versus adults (14,751.4 vs. 17,102.9 ng/h/mL); the geometric mean ratio (GMR; pediatric:adult) was 0.86 [90% confidence interval (CI), 0.70-1.06].",Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31676669/),[ng] / [hÂ·ml],"17,102.9",221032,DB00619,Imatinib
,15963092,apparent clearance (CL),"Population mean estimates (95% confidence interval) at day 1 for apparent clearance (CL) and apparent volume of distribution (V) of imatinib were 14 (13-15) l h(-1) and 252 (237-267) l, respectively.",Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963092/),[l] / [h],14,221371,DB00619,Imatinib
,15963092,apparent volume of distribution (V),"Population mean estimates (95% confidence interval) at day 1 for apparent clearance (CL) and apparent volume of distribution (V) of imatinib were 14 (13-15) l h(-1) and 252 (237-267) l, respectively.",Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963092/),l,252,221372,DB00619,Imatinib
>,32450392,IC50,"First, to ensure the safety of our hits, investigation of the IC50 values on normal human cells (WI-38) was executed indicating that, they are highly selective (IC50 > 107 Î¼M) in their cytotoxic effect.","In vitro cytotoxic activity of thiazole-indenoquinoxaline hybrids as apoptotic agents, design, synthesis, physicochemical and pharmacokinetic studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32450392/),Î¼M,107,222807,DB00619,Imatinib
,31550823,plasma concentrations,"The IM plasma concentrations were significantly different between the doses of 300 mg/d and 400 mg/d [(942.4Â±433.5) Î¼g/L vs. (1340.0Â±500.1) Î¼g/L, t=6.317, P<0.001], and between 400 mg/d and 600 mg/d [(1340.0Â±500.1) Î¼g/L vs. (2188.0Â±875.5) Î¼g/L, t=3.557, P=0.004].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[Î¼g] / [l],942.4,224788,DB00619,Imatinib
,31550823,plasma concentrations,"The IM plasma concentrations were significantly different between the doses of 300 mg/d and 400 mg/d [(942.4Â±433.5) Î¼g/L vs. (1340.0Â±500.1) Î¼g/L, t=6.317, P<0.001], and between 400 mg/d and 600 mg/d [(1340.0Â±500.1) Î¼g/L vs. (2188.0Â±875.5) Î¼g/L, t=3.557, P=0.004].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[Î¼g] / [l],1340.0,224789,DB00619,Imatinib
,31550823,plasma concentrations,"The IM plasma concentrations were significantly different between the doses of 300 mg/d and 400 mg/d [(942.4Â±433.5) Î¼g/L vs. (1340.0Â±500.1) Î¼g/L, t=6.317, P<0.001], and between 400 mg/d and 600 mg/d [(1340.0Â±500.1) Î¼g/L vs. (2188.0Â±875.5) Î¼g/L, t=3.557, P=0.004].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[Î¼g] / [l],2188.0,224790,DB00619,Imatinib
,31550823,plasma concentration,"Among the blood samples of 57 patients receiving IM 300 mg/d, the IM plasma concentration of the advanced patients was significantly lower than that of the non-advanced patients [(795.6Â±225.8) Î¼g/L vs. (992.2Â±484.4) Î¼g/L, t=2.088, P=0.042].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[Î¼g] / [l],795.6,224791,DB00619,Imatinib
,31550823,plasma concentration,"Among the blood samples of 57 patients receiving IM 300 mg/d, the IM plasma concentration of the advanced patients was significantly lower than that of the non-advanced patients [(795.6Â±225.8) Î¼g/L vs. (992.2Â±484.4) Î¼g/L, t=2.088, P=0.042].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[Î¼g] / [l],992.2,224792,DB00619,Imatinib
,31550823,plasma concentration,"Among the 137 blood samples of patients receiving IM 400 mg/d, the IM plasma concentration was higher in patients aged >60 years than those aged â¤60 years [(1461.0Â±595.3) Î¼g/L vs. (1240.0Â±380.9) Î¼g/L, t=2.528, P=0.013] and the IM plasma concentration of cases with diarrhea was significantly lower than that of those without diarrhea [(745.8Â±249.6) Î¼g/L vs. (1382.0Â±486.9) Î¼g/L, t=6.794, P<0.001].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[Î¼g] / [l],1461.0,224793,DB00619,Imatinib
,31550823,plasma concentration,"Among the 137 blood samples of patients receiving IM 400 mg/d, the IM plasma concentration was higher in patients aged >60 years than those aged â¤60 years [(1461.0Â±595.3) Î¼g/L vs. (1240.0Â±380.9) Î¼g/L, t=2.528, P=0.013] and the IM plasma concentration of cases with diarrhea was significantly lower than that of those without diarrhea [(745.8Â±249.6) Î¼g/L vs. (1382.0Â±486.9) Î¼g/L, t=6.794, P<0.001].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[Î¼g] / [l],1240.0,224794,DB00619,Imatinib
,31550823,plasma concentration,"Among the 137 blood samples of patients receiving IM 400 mg/d, the IM plasma concentration was higher in patients aged >60 years than those aged â¤60 years [(1461.0Â±595.3) Î¼g/L vs. (1240.0Â±380.9) Î¼g/L, t=2.528, P=0.013] and the IM plasma concentration of cases with diarrhea was significantly lower than that of those without diarrhea [(745.8Â±249.6) Î¼g/L vs. (1382.0Â±486.9) Î¼g/L, t=6.794, P<0.001].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[Î¼g] / [l],745.8,224795,DB00619,Imatinib
,31550823,plasma concentration,"Among the 137 blood samples of patients receiving IM 400 mg/d, the IM plasma concentration was higher in patients aged >60 years than those aged â¤60 years [(1461.0Â±595.3) Î¼g/L vs. (1240.0Â±380.9) Î¼g/L, t=2.528, P=0.013] and the IM plasma concentration of cases with diarrhea was significantly lower than that of those without diarrhea [(745.8Â±249.6) Î¼g/L vs. (1382.0Â±486.9) Î¼g/L, t=6.794, P<0.001].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[Î¼g] / [l],1382.0,224796,DB00619,Imatinib
,27028877,Ki,"These studies revealed that AM-1-124, possessing a 2,3,5,6-tetrafluorophenylsulfonamide group, retained STAT3 protein affinity (Ki =15 Î¼m), as well as selectivity over STAT1 (Ki >250 Î¼m).",Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27028877/),Î¼m,15,228942,DB00619,Imatinib
>,27028877,Ki,"These studies revealed that AM-1-124, possessing a 2,3,5,6-tetrafluorophenylsulfonamide group, retained STAT3 protein affinity (Ki =15 Î¼m), as well as selectivity over STAT1 (Ki >250 Î¼m).",Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27028877/),Î¼m,250,228943,DB00619,Imatinib
,27028877,t1/2,"Moreover, in both hepatocytes and in in vivo pharmacokinetic studies (CD-1 mice), AM-1-124 was found to be dramatically more stable than SH-4-054 (t1/2 =1.42 h cf. 10 min, respectively).",Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27028877/),h,1.42,228944,DB00619,Imatinib
,27028877,t1/2,"Moreover, in both hepatocytes and in in vivo pharmacokinetic studies (CD-1 mice), AM-1-124 was found to be dramatically more stable than SH-4-054 (t1/2 =1.42 h cf. 10 min, respectively).",Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27028877/),min,10,228945,DB00619,Imatinib
,27245313,IPC,"The median IPC achieved with branded imatinib was 1454 Î¼mol/L (range, 485-2707 Î¼mol/L) with 18 patients (75%) having IPC â¥ 1000 Î¼mol/L.",Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245313/),[Î¼M] / [l],1454,229977,DB00619,Imatinib
,27245313,IPCs,"For Neopax and Imakrebin, median IPCs were 1717 Î¼mol/L (range, 1249-3630 Î¼mol/L) and 1458 Î¼mol/L (range, 707-880 Î¼mol/L), respectively, with 11 of 11 (100%) and 16 of 18 (89%) patients having IPC â¥ 1000 Î¼mol/L.",Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245313/),[Î¼M] / [l],1717,229978,DB00619,Imatinib
,27245313,IPCs,"For Neopax and Imakrebin, median IPCs were 1717 Î¼mol/L (range, 1249-3630 Î¼mol/L) and 1458 Î¼mol/L (range, 707-880 Î¼mol/L), respectively, with 11 of 11 (100%) and 16 of 18 (89%) patients having IPC â¥ 1000 Î¼mol/L.",Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245313/),[Î¼M] / [l],1458,229979,DB00619,Imatinib
<,23396605,Cure rate,Cure rate for subjects with refractory or relapsing metastatic neuroblastoma is <5%.,Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23396605/),%,5,237399,DB00619,Imatinib
,23396605,exposure,"At steady-state, PK exposure (69.7 Âµg h/ml) was similar to that of adults receiving 1000 mg/die.",Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23396605/),[hÂ·Î¼g] / [ml],69.7,237400,DB00619,Imatinib
under,24844604,initial trough concentrations,"First, individual initial trough concentrations under 400mg/day imatinib starting dose were estimated.",Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24844604/),[mg] / [d],400,240493,DB00619,Imatinib
,24844604,Cmin,Time-point independent multivariate regression confirmed a correlation of individual Cmin(400mg) with response and adverse events.,Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24844604/),,400,240494,DB00619,Imatinib
,23574742,flow rate,"High-performance liquid chromatographic separation was performed on a Thermo BDS Hypersil C18 column (4.6 Ã 100 mm, 2.4 Âµm) with methanol-water (55:45, v/v) containing 0.1% formic acid and 0.2% ammonium acetate as the mobile phase, using isocratic elution at a flow rate of 0.7 mL/min.",LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23574742/),[ml] / [min],0.7,242450,DB00619,Imatinib
,31006038,progression-free survival,Median progression-free survival was 5.8 months (95% CI 2.3-not reached).,Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31006038/),month,5.8,242507,DB00619,Imatinib
,24036846,area under the plasma concentration versus time curve,"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 Î¼g/mL h alone vs. 16.9 Î¼g/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 Î¼g/mL alone vs. 6.18 Î¼g/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),[Î¼g] / [hÂ·ml],18.4,251791,DB00619,Imatinib
,24036846,area under the plasma concentration versus time curve,"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 Î¼g/mL h alone vs. 16.9 Î¼g/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 Î¼g/mL alone vs. 6.18 Î¼g/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),[Î¼g] / [hÂ·ml],16.9,251792,DB00619,Imatinib
,24036846,maximum plasma concentration (C(max)),"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 Î¼g/mL h alone vs. 16.9 Î¼g/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 Î¼g/mL alone vs. 6.18 Î¼g/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),[Î¼g] / [ml],0.670,251793,DB00619,Imatinib
,24036846,maximum plasma concentration (C(max)),"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 Î¼g/mL h alone vs. 16.9 Î¼g/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 Î¼g/mL alone vs. 6.18 Î¼g/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),[Î¼g] / [ml],6.18,251794,DB00619,Imatinib
,24036846,half-life,"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 Î¼g/mL h alone vs. 16.9 Î¼g/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 Î¼g/mL alone vs. 6.18 Î¼g/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),h,18.9,251795,DB00619,Imatinib
,24036846,half-life,"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 Î¼g/mL h alone vs. 16.9 Î¼g/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 Î¼g/mL alone vs. 6.18 Î¼g/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),h,17.2,251796,DB00619,Imatinib
more,16803422,bioavailability,"Although the bioavailability of imatinib mesylate is more than 97%, the exact gastrointestinal site of its absorption is unknown.",Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16803422/),%,97,252277,DB00619,Imatinib
,18094422,area under the curve,"In 11 evaluable patients, the geometric mean (95% confidence interval) area under the curve of imatinib on days 1 and 4 were 42.6 (33.0-54.9) microg.h/mL and 41.2 (32.1-53.1) microg.h/mL, respectively (P = 0.65).",Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094422/),[hÂ·Î¼g] / [ml],42.6,252966,DB00619,Imatinib
,18094422,area under the curve,"In 11 evaluable patients, the geometric mean (95% confidence interval) area under the curve of imatinib on days 1 and 4 were 42.6 (33.0-54.9) microg.h/mL and 41.2 (32.1-53.1) microg.h/mL, respectively (P = 0.65).",Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094422/),[hÂ·Î¼g] / [ml],41.2,252967,DB00619,Imatinib
,24060561,Cmax,"The observed mean (SD) Cmax, AUC0-last, and AUC0-â values for the reference formulation were 1792 (357) ng/mL, 28,485 (6274) ng Â· h/mL, and 29,079 (6371) ng Â· h/mL, respectively.","Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24060561/),[ng] / [ml],1792,255050,DB00619,Imatinib
,24060561,AUC0-last,"The observed mean (SD) Cmax, AUC0-last, and AUC0-â values for the reference formulation were 1792 (357) ng/mL, 28,485 (6274) ng Â· h/mL, and 29,079 (6371) ng Â· h/mL, respectively.","Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24060561/),[hÂ·ng] / [ml],"28,485",255051,DB00619,Imatinib
,24060561,AUC0-â,"The observed mean (SD) Cmax, AUC0-last, and AUC0-â values for the reference formulation were 1792 (357) ng/mL, 28,485 (6274) ng Â· h/mL, and 29,079 (6371) ng Â· h/mL, respectively.","Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24060561/),[hÂ·ng] / [ml],"29,079",255052,DB00619,Imatinib
,29404062,flow rate,The flow rate was 0.25 mL/min and the total run time was 6 min.,"A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),[ml] / [min],0.25,256216,DB00619,Imatinib
,29404062,total run time,The flow rate was 0.25 mL/min and the total run time was 6 min.,"A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),min,6,256217,DB00619,Imatinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5â394.5 for imatinib, 488.7â401.5 for dasatinib, 530.7â289.5 for nilotinib and 528.5â403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,494.5,256218,DB00619,Imatinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5â394.5 for imatinib, 488.7â401.5 for dasatinib, 530.7â289.5 for nilotinib and 528.5â403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,394.5,256219,DB00619,Imatinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5â394.5 for imatinib, 488.7â401.5 for dasatinib, 530.7â289.5 for nilotinib and 528.5â403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,488.7,256220,DB00619,Imatinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5â394.5 for imatinib, 488.7â401.5 for dasatinib, 530.7â289.5 for nilotinib and 528.5â403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,530.7,256221,DB00619,Imatinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5â394.5 for imatinib, 488.7â401.5 for dasatinib, 530.7â289.5 for nilotinib and 528.5â403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,289.5,256222,DB00619,Imatinib
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5â394.5 for imatinib, 488.7â401.5 for dasatinib, 530.7â289.5 for nilotinib and 528.5â403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,528.5,256223,DB00619,Imatinib
,22180047,Plasma terminal elimination half-lives,"Plasma terminal elimination half-lives of sunitinib were 8 h in rats, 17 h in monkeys, and 51 h in humans.","Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22180047/),h,8,258264,DB00619,Imatinib
,22180047,Plasma terminal elimination half-lives,"Plasma terminal elimination half-lives of sunitinib were 8 h in rats, 17 h in monkeys, and 51 h in humans.","Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22180047/),h,17,258265,DB00619,Imatinib
,22180047,Plasma terminal elimination half-lives,"Plasma terminal elimination half-lives of sunitinib were 8 h in rats, 17 h in monkeys, and 51 h in humans.","Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22180047/),h,51,258266,DB00619,Imatinib
,22180047,bioavailability,"The bioavailability in female rats was close to 100%, suggesting complete absorption of sunitinib.","Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22180047/),%,100,258267,DB00619,Imatinib
,34011155,IC50,"As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively.","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),nM,0.4,263570,DB00619,Imatinib
,34011155,IC50,"As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively.","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),nM,0.1,263571,DB00619,Imatinib
,34011155,IC50,"As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively.","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),nM,2.1,263572,DB00619,Imatinib
,34011155,IC50,"As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively.","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),nM,4.7,263573,DB00619,Imatinib
,34011155,oral bioavailability,"It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 hÂ·ng/mL).","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),%,32,263574,DB00619,Imatinib
,34011155,half-life,"It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 hÂ·ng/mL).","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),h,4.61,263575,DB00619,Imatinib
,34011155,exposure,"It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 hÂ·ng/mL).","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),[hÂ·ng] / [ml],1386,263576,DB00619,Imatinib
,14658008,AUC,"We present here pharmacokinetic data obtained with a newly designed HPLC approach in 97 patients with chronic myeloid leukemia or acute lymphatic leukemia (ALL) under treatment with imatinib that allowed us to calculate the AUC (39.5 microg.h/ml for an oral dose of 400 mg daily), the t(1/2) (18.2 h) and the peak concentration (1.92 micro/ml for an oral dose of 400 mg daily) of imatinib in plasma.",Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658008/),[hÂ·Î¼g] / [ml],39.5,264939,DB00619,Imatinib
,14658008,t(1/2),"We present here pharmacokinetic data obtained with a newly designed HPLC approach in 97 patients with chronic myeloid leukemia or acute lymphatic leukemia (ALL) under treatment with imatinib that allowed us to calculate the AUC (39.5 microg.h/ml for an oral dose of 400 mg daily), the t(1/2) (18.2 h) and the peak concentration (1.92 micro/ml for an oral dose of 400 mg daily) of imatinib in plasma.",Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658008/),h,18.2,264940,DB00619,Imatinib
,14658008,peak concentration,"We present here pharmacokinetic data obtained with a newly designed HPLC approach in 97 patients with chronic myeloid leukemia or acute lymphatic leukemia (ALL) under treatment with imatinib that allowed us to calculate the AUC (39.5 microg.h/ml for an oral dose of 400 mg daily), the t(1/2) (18.2 h) and the peak concentration (1.92 micro/ml for an oral dose of 400 mg daily) of imatinib in plasma.",Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658008/),[Î¼] / [ml],1.92,264941,DB00619,Imatinib
,19723647,CL/F,"Oral clearance (CL/F) of nilotinib was similar across the combination groups (mean CL/F, 19.1-25.6 L/h), and lower than in the single-agent cohort (mean CL/F, 35.6 L/h).",A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723647/),[l] / [h],19.1-25.6,266108,DB00619,Imatinib
,19723647,CL/F,"Oral clearance (CL/F) of nilotinib was similar across the combination groups (mean CL/F, 19.1-25.6 L/h), and lower than in the single-agent cohort (mean CL/F, 35.6 L/h).",A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723647/),[l] / [h],35.6,266109,DB00619,Imatinib
,19723647,progression-free survival,Thirty-eight patients had stable disease and two patients achieved partial response with a median progression-free survival of 134 days for the entire group.,A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723647/),d,134,266110,DB00619,Imatinib
,26693810,metabolic ratio,"Patients with optimal response to imatinib after 12 months of therapy did not differ in CYP3A activity compared to nonoptimal responders (quinine metabolic ratio of 14.69 and 14.70, respectively; P = 0.966).",In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26693810/),,14.69,266876,DB00619,Imatinib
,26693810,metabolic ratio,"Patients with optimal response to imatinib after 12 months of therapy did not differ in CYP3A activity compared to nonoptimal responders (quinine metabolic ratio of 14.69 and 14.70, respectively; P = 0.966).",In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26693810/),,14.,266877,DB00619,Imatinib
less,32250458,ki,All three compounds showed a strong reversible inhibition on CYP2C8 enzyme with ki of less than 0.5 Î¼mol L-1 .,"Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),[Î¼M] / [l],0.5,267402,DB00619,Imatinib
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.0,267403,DB00619,Imatinib
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.1,267404,DB00619,Imatinib
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.4,267405,DB00619,Imatinib
,32250458,AUC ratio,"The PBPK simulation predicted that at recommended dosing regimens of S. sphenanthera, co-administration would result in an increase in bosutinib exposure (AUC ratio 3.0) but not in imatinib exposure.","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,3.0,267406,DB00619,Imatinib
,14612892,half-life,There was a statistically significant decrease in total-body clearance of drug from the plasma (CL/F) with a mean reduction of 70% for simvastatin (P<0.001): the mean half-life of simvastatin was prolonged from 1.4-2.7 h when given together with imatinib.,"Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14612892/),h,1.4-2.7,268235,DB00619,Imatinib
,28703026,fetal/maternal,The fetal/maternal concentration ratio ranged from 0.5 to 0.58 for nilotinib and from 0.05 to 0.22 for imatinib.,Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28703026/),,0.5 to 0.58,272680,DB00619,Imatinib
,28703026,concentration ratio,The fetal/maternal concentration ratio ranged from 0.5 to 0.58 for nilotinib and from 0.05 to 0.22 for imatinib.,Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28703026/),,0.5 to 0.58,272681,DB00619,Imatinib
,28703026,concentration ratio,The fetal/maternal concentration ratio ranged from 0.5 to 0.58 for nilotinib and from 0.05 to 0.22 for imatinib.,Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28703026/),,0.05 to 0.22,272682,DB00619,Imatinib
